var title_f21_24_21888="Staphylococcal abscess";
var content_f21_24_21888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Staphylococcal abscess on the neck of a patient with hyperimmunoglobulin E syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21888=[""].join("\n");
var outline_f21_24_21888=null;
var title_f21_24_21889="Zenith iliac branch device";
var content_f21_24_21889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Zenith iliac branch device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Permission for use granted by Cook Medical Incorporated, Bloomington, Indiana.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21889=[""].join("\n");
var outline_f21_24_21889=null;
var title_f21_24_21890="M ozzardi microfilariae";
var content_f21_24_21890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    M. ozzardi microfilariae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microfilariae of M. ozzardi in thick blood smears stained with Giemsa. Microfilariae of Mansonella ozzardi are unsheathed and measure 160 to 205 micrometers in stained blood smears and 200 to 255 micrometers in 2% formalin. The tail tapers to a point, and the nuclei end well before the end of the tail. The end of the tail is also bent in a small hook-like shape. Microfilariae circulate in the blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Filariasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/imagelibrary/Filariasis_il.htm\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/imagelibrary/Filariasis_il.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21890=[""].join("\n");
var outline_f21_24_21890=null;
var title_f21_24_21891="Ethionamide: Pediatric drug information";
var content_f21_24_21891=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethionamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"    see \"Ethionamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/2/26660?source=see_link\">",
"    see \"Ethionamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trecator&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Trecator&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitubercular Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"      see \"Ethionamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 15-20 mg/kg/day in 2-3 divided doses, not to exceed 1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 500-1000 mg/day in 1-3 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trecator&reg;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with meals to decrease GI distress",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In conjunction with other antituberculosis agents in the treatment of tuberculosis and other mycobacterial diseases",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F168697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, drowsiness, headache, psychiatric disturbances, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, photosensitivity, purpura, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia, hypoglycemia, hypothyroidism or goiter, menstrual irregularities, pellagra-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, excessive salivation, metallic taste, nausea, stomatitis, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, hepatitis, jaundice, liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, peripheral neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, optic neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Olfactory disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethionamide or any component; severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with diabetes mellitus; may cause hypoglycemia. Use not recommended in patients with porphyria; porphyria-inducing in animal and",
"     <i>",
"      in vitro",
"     </i>",
"     studies (WHO, 2008). Use with caution in patients with thyroid dysfunction; hypothyroidism (reversible) has been reported. Use with caution in patients receiving isoniazid; temporarily increases isoniazid levels. Some cross-resistance has been reported if inhA mutation is present (WHO, 2008). Use with caution in patients receiving cycloserine; seizures have been reported. Periodic eye exams are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16337633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause hepatotoxicity; monitor liver function tests monthly. Drug-resistant tuberculosis develops rapidly if ethionamide is used alone; must administer with at least one other antituberculosis agent.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Ethionamide. Specifically, there may be a risk for a psychotic episode/reaction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSERINE: Ethionamide may enhance the adverse/toxic effect of CycloSERINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Ethionamide may increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1047316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase dietary intake of pyridoxine to prevent neurotoxic effects of ethionamide",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethionamide crosses the placenta; teratogenic effects were observed in animal studies. Use during pregnancy is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial and periodic serum AST and ALT, blood glucose, thyroid function tests, periodic ophthalmologic exams",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits peptide synthesis in susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &sim;80% is rapidly absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; widely distributed into body tissues and fluids including liver, kidneys, and CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to active and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: As metabolites (active and inactive) and parent drug in the urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/24/21891/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donald PR and Seifart HI,&ldquo;Cerebrospinal Fluid Concentrations of Ethionamide in Children With Tuberculous Meningitis,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 115(3):483-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/24/21891/abstract-text/2769511 /pubmed\" id=\"2769511 \" target=\"_blank\">",
"        2769511",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(6):455-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/24/21891/abstract-text/7667049/pubmed\" id=\"7667049\" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13287 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21891=[""].join("\n");
var outline_f21_24_21891=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168672\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168673\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047308\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047302\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168646\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168633\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047311\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047310\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168697\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047314\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047301\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337633\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299299\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220232\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047316\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168642\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168656\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047307\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047300\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047313\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13287\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13287|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=related_link\">",
"      Ethionamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/2/26660?source=related_link\">",
"      Ethionamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_24_21892="Bullous pemphigoid tense bullae 2";
var content_f21_24_21892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple tense bullae on skin with one eroded blister base.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21892=[""].join("\n");
var outline_f21_24_21892=null;
var title_f21_24_21893="Azilsartan: Patient drug information";
var content_f21_24_21893=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azilsartan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/37/32342?source=see_link\">",
"     see \"Azilsartan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11820546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Edarbi&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16053034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Edarbi&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12584758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12584760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given to you for other reasons. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12584759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3361293",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to azilsartan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4231030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt or salt-free diet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194403",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This is not a list of all drugs or health problems that interact with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4199493",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you take any drugs (prescription or OTC, natural products, vitamins) that must not be taken with this drug, like certain drugs that are used for HIV, infections, or depression. There are many drugs that must not be taken with this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12584764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4201327",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To lower the chance of feeling dizzy or passing out, rise slowly over a few minutes when sitting or lying down. Be careful climbing stairs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4231042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you drink wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may not work as well in black patients. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 65 or older, use this drug with care. You could have more side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12584765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor if any of these side effects or any other side effects bother you:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12584767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these side effects:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unable to pass urine or change in the amount of urine passed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4270262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fast or slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4186197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at",
"       <a href=\"file://www.fda.gov/medwatch\" target=\"_blank\">",
"        file://www.fda.gov/medwatch",
"       </a>",
"       .",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to Health Canada's Canada Vigilance Program at 1-866-234-2345.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12584762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12584763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12584768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in the original container at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12584769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16476 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21893=[""].join("\n");
var outline_f21_24_21893=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11820546\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16053034\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584758\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584760\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584759\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584764\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584765\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584767\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584762\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584763\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584768\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12584769\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/37/32342?source=related_link\">",
"      Azilsartan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_24_21894="Depression treatment options for adults";
var content_f21_24_21894=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Depression treatment options for adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/24/21894/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21894/contributors\" id=\"au3999\">",
"       Wayne Katon, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21894/contributors\" id=\"au4075\">",
"       Paul Ciechanowski, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/24/21894/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21894/contributors\" id=\"se7050\">",
"       Thomas L Schwenk, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/24/21894/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21894/contributors\" id=\"de3194\">",
"       David Solomon, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?21/24/21894?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DEPRESSION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Depression is a treatable condition. However, many people are reluctant to accept a diagnosis of depression and pursue treatment. A person may worry about the social stigma of depression and may be embarrassed to discuss the need for treatment with family or friends. In addition, some people do not understand that physical problems such as aches and pains, fatigue, and difficulty sleeping can be caused by depression.",
"    </p>",
"    <p>",
"     Fortunately, early and successful treatment of depression shortens the duration of illness, reduces the likelihood of persistent symptoms, and reduces the likelihood of a relapse.",
"    </p>",
"    <p>",
"     The treatment of depression may include psychotherapy (counseling), drug therapy, or some combination of these therapies. In many cases, depression can be treated by a primary care provider.",
"    </p>",
"    <p>",
"     This topic review discusses the treatment options available for adults with depression. A topic review that discusses the cause, symptoms, and diagnosis of depression is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"      \"Patient information: Depression in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PREVENTING SUICIDE",
"     </span>",
"    </p>",
"    <p>",
"     Suicide is a tragic and preventable consequence of severe depression. If a clinician suspects that you are depressed, he or she will often ask about suicidal thoughts. It is absolutely imperative to tell your clinician if you have thoughts about harming yourself or ending your life. If you are concerned that you or someone you know is at risk of hurting him or herself or others, you should do one of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Call a healthcare provider for advice or an urgent appointment",
"      </li>",
"      <li>",
"       Take the person to the local emergency department",
"      </li>",
"      <li>",
"       Call the National Suicide Prevention Lifeline (",
"       <a class=\"external\" href=\"file://www.suicidepreventionlifeline.org/\">",
"        www.suicidepreventionlifeline.org",
"       </a>",
"       ) at 1-800-273-TALK (8255)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A person who is at immediate risk for attempting suicide requires emergency evaluation and prompt treatment for depression (if depression precipitated the suicidal thoughts). This may include hospitalization, antidepressant medication, and intensive therapy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ANTIDEPRESSANTS VERSUS PSYCHOTHERAPY",
"     </span>",
"    </p>",
"    <p>",
"     People with severe depression generally require one or more antidepressant medications to treat their symptoms, sometimes along with psychotherapy. Combination therapy (counseling and antidepressant medication) may be especially helpful for those who have severe depression or a history of recurrent depression. Mild or moderate depression can probably be treated with either drug therapy or psychotherapy. There are no clear predictors of which therapy is a better choice for any given individual.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      PSYCHOTHERAPY TO TREAT DEPRESSION",
"     </span>",
"    </p>",
"    <p>",
"     Psychotherapy (sometimes called therapy or counseling) is a process during which a person talks to a healthcare professional about their feelings, relationships, and worries. During a therapy session, the patient and therapist can discuss alternate ways of thinking or feeling about a situation, which often helps the patient to cope with depressive symptoms, improve social skills, and increase self-confidence.",
"    </p>",
"    <p>",
"     There are several different types of psychotherapy. Therapy sessions are usually conducted in the therapist's office once per week for 30 to 60 minutes. In the early stages of treatment, one or more sessions per week may be recommended. As the treatment progresses, the frequency of meetings can sometimes be reduced to once every other week. The patient and therapist should work together to determine the optimal schedule.",
"    </p>",
"    <p>",
"     The initial therapy sessions often focus on trying to understand why you are depressed, and may include simple homework activities to identify the factors that may be contributing to depression. Although psychotherapy can improve symptoms of depression within several weeks, the greatest benefit of therapy may not be seen for 8 to 10 weeks or longer.",
"    </p>",
"    <p>",
"     Psychotherapy can be provided by any licensed healthcare professional who has appropriate training, including a psychiatrist, psychologist, clinical social worker, or clinical nurse specialist.",
"    </p>",
"    <p>",
"     People with severe depression and those at risk for suicide are often hospitalized in a psychiatric facility for a short period of time. During the hospitalization, the person usually meets with a psychiatrist to manage medications. Therapy sessions are also part of the treatment. Other activities, such as group therapy sessions and physical exercise, are often encouraged.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      ANTIDEPRESSANT MEDICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     If your therapist feels that you need an antidepressant medication, you may be referred to a psychiatrist or your primary care provider. A psychiatrist is a medical doctor with specialized training in the treatment of mental health issues. In some cases, a psychiatrist provides counseling and prescribes medications if needed; in other cases, a therapist provides counseling, and a psychiatrist prescribes medication.",
"    </p>",
"    <p>",
"     Therapy with an antidepressant medication helps reestablish the normal balance of chemicals in the brain. Several different classes of antidepressants effectively relieve the symptoms of depression.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Time required for a response",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people respond to antidepressant medication after about two weeks, but for most, the full effect is not seen until four to six weeks or longer. During the first few weeks, the dose is usually increased gradually. The person usually sees the medical provider (the psychiatrist or primary care provider) once every one or two weeks for the first few weeks, then less frequently; if problems develop at any point, more frequent visits may be recommended.",
"    </p>",
"    <p>",
"     By six to eight weeks after starting an antidepressant medication, it is usually possible to determine if the medication is effective. If your symptoms have improved somewhat during this time, the dose of the medication may be increased, or a second medication may be started. If there has been no improvement in symptoms, an alternate antidepressant medication may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Duration",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most cases, antidepressant medications are recommended for at least six to nine months. This amount of time varies greatly depending upon your situation. The decision to stop antidepressant medication should be shared between you and your provider.",
"    </p>",
"    <p>",
"     People who experience depression as a result of an event (such as a major stress or loss), should continue taking antidepressant medication until the emotional response to the event has been fully addressed.",
"    </p>",
"    <p>",
"     When antidepressants are stopped, they should be tapered slowly over two to four weeks to minimize the potential side effects associated with abruptly stopping medication. Side effects associated with stopping medication quickly can include jitteriness, dizziness, nausea, fatigue, muscle aches, chills, anxiety, and irritability. Although these symptoms are not dangerous and usually improve over one to two weeks, they can be quite distressing and uncomfortable.",
"    </p>",
"    <p>",
"     In people with major depression, a relapse in symptoms is relatively common after stopping treatment with an antidepressant; in some cases, longer-term treatment is recommended (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Maintenance drug therapy'",
"     </a>",
"     below)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Maintenance drug therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Maintenance antidepressant therapy (long-term drug therapy) may be appropriate for people who are at risk for a relapse of depression. One study found that 37 percent of people who were treated for depression experienced a relapse within 12 months of stopping antidepressant therapy [",
"     <a class=\"abstract\" href=\"UTD.htm?21/24/21894/abstract/1\">",
"      1",
"     </a>",
"     ]. Maintenance therapy may last from one year to indefinitely, depending upon the individual's situation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Therapy with other medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some people, depression is accompanied by other psychiatric conditions, such as panic attacks or mania. Clinicians may therefore recommend using combination therapy, including an antidepressant and one or more antipsychotic, antianxiety, mood-stabilizing, or anticonvulsant medications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      CHOICE OF ANTIDEPRESSANTS",
"     </span>",
"    </p>",
"    <p>",
"     Many different classes of antidepressants are effective for relieving depression [",
"     <a class=\"abstract\" href=\"UTD.htm?21/24/21894/abstract/2\">",
"      2",
"     </a>",
"     ]. Thus, the choice among antidepressants depends upon other factors, including whether the person has other medical conditions, takes medications that could interact with the antidepressant, and the impact of potential antidepressant side effects.",
"    </p>",
"    <p>",
"     When considering use of an antidepressant, is important to do the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Discuss the expected benefits before starting treatment",
"      </li>",
"      <li>",
"       Be aware of possible side effects of antidepressants",
"      </li>",
"      <li>",
"       Follow the instructions for the dose and timing",
"      </li>",
"      <li>",
"       Avoid combining antidepressants unless you are instructed to do so",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Selective serotonin reuptake inhibitors (SSRIs)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Drugs in this class include fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine, and escitalopram (",
"     <a class=\"graphic graphic_table graphicRef81374 \" href=\"UTD.htm?42/3/43069\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The selective serotonin reuptake inhibitors (SSRIs) increase brain levels of the neurochemical serotonin. Low levels of serotonin may be one cause of depression.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Compared with most other antidepressants, the SSRIs have relatively few side effects. The most common side effects include jitteriness, restlessness, agitation, headache, diarrhea and nausea, and insomnia.",
"    </p>",
"    <p>",
"     Sexual side effects (loss of sexual desire, diminished arousal, and difficulty having an orgasm) may also occur with prolonged use of the SSRIs; however, adding another drug (such as bupropion or buspirone) can sometimes relieve these sexual side effects. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"      \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"      \"Patient information: Sexual problems in women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Serotonin syndrome &mdash; A more serious potential side effect of SSRIs is serotonin syndrome. Symptoms of serotonin syndrome can include agitation, confusion, and overheating (hyperthermia). This can occur with taking an overdose of an SSRI or if an SSRI is taken in combination with another antidepressant medication called a monoamine oxidase inhibitor (MAOI).",
"       <br/>",
"       <br/>",
"       There is a very small risk of serotonin syndrome when an SSRI is combined with a class of migraine medications called triptans (eg, sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan). Many headache experts feel that it is safe to use an SSRI and a triptan in combination as long as the person is monitored for symptoms.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Mirtazapine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mirtazapine is another antidepressant. This drug changes the levels of several neurochemicals in the brain, including serotonin. Mirtazapine has antianxiety and sedative effects and may be especially effective in people with depression who have symptoms of anxiety and insomnia.",
"    </p>",
"    <p>",
"     The side effects of mirtazapine include sedation, which is more common at lower drug doses. Other side effects include increased appetite, weight gain, and dry mouth (",
"     <a class=\"graphic graphic_table graphicRef81374 \" href=\"UTD.htm?42/3/43069\">",
"      table 1",
"     </a>",
"     ). Mirtazapine is less likely than other antidepressants to have sexual side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Bupropion",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bupropion is an antidepressant that changes the level of several neurochemicals in the brain but does not appear to have any direct effect on levels of serotonin. Bupropion has a mild stimulant action and may be especially effective in people with depression who have fatigue or poor concentration.",
"    </p>",
"    <p>",
"     Bupropion has few side effects, but it has been associated with seizures in people with eating disorders; it is not recommended for people who have bulimia or anorexia. The drug carries a small risk of seizures in other people. Other side effects of bupropion may include mild anxiety or insomnia and decreased appetite with weight loss (",
"     <a class=\"graphic graphic_table graphicRef81374 \" href=\"UTD.htm?42/3/43069\">",
"      table 1",
"     </a>",
"     ). Unlike other antidepressants, bupropion does not have sexual side effects. It is sometimes used at low doses to help counter the sexual side effects of other antidepressants.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Serotonin norepinephrine reuptake inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;The serotonin norepinephrine reuptake inhibitors venlafaxine, desvenlafaxine, and duloxetine alter levels of several different neurochemicals in the brain. For unknown reasons, these drugs may be especially effective in people who have a poor response to other antidepressants. Duloxetine may be of benefit in persons with depression, as well as pain from medical (eg, arthritis) or orthopaedic (eg, spinal disc disease) conditions, although there have not been studies comparing duloxetine with other antidepressants for this purpose.",
"    </p>",
"    <p>",
"     Common side effects include nausea, dizziness, insomnia, sedation, and constipation. Rarely, these drugs also cause increased sweating (",
"     <a class=\"graphic graphic_table graphicRef81374 \" href=\"UTD.htm?42/3/43069\">",
"      table 1",
"     </a>",
"     ). People taking venlafaxine should have regular blood pressure checks, since it may cause blood pressure to rise.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Tricyclic antidepressants",
"     </span>",
"     &nbsp;&mdash;&nbsp;The tricyclic antidepressants alter levels of several different neurochemicals in the brain. Drugs in this class include imipramine, amitriptyline, desipramine, nortriptyline, and clomipramine.",
"    </p>",
"    <p>",
"     Because of the numerous side effects associated with these drugs and the availability of other antidepressants, the tricyclic antidepressants are less commonly used as first-line antidepressant therapy.",
"    </p>",
"    <p>",
"     The side effects of tricyclic antidepressants may include dry mouth, blurred vision, constipation, nausea, difficulty urinating, drowsiness, weight gain, sexual problems, and rapid heartbeat. In older adults, the side effects may include memory impairment, confusion, and hallucinations.",
"    </p>",
"    <p>",
"     The most worrisome side effects of the tricyclic antidepressants are irregular heartbeats and sudden death. If you are under age 40, your doctor will ask you questions about your heart to make sure you are not at risk for these complications. If you are over age 40, you will have to have a normal ECG (electrocardiogram, heart tracing) before you can take a tricyclic antidepressant.",
"    </p>",
"    <p>",
"     It is important to remember that most people use these drugs safely, and their antidepressant activity is similar to that of antidepressants from other classes.",
"    </p>",
"    <p>",
"     When you are stopping a tricyclic medicine, it is important to taper slowly over several days to a few weeks to prevent withdrawal symptoms (aches, chills, stomach distress).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Monoamine oxidase (MAO) inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;The monoamine oxidase (MAO) inhibitors were the first drugs used to treat depression. These drugs block an enzyme that breaks down neurochemicals. Drugs in this class include tranylcypromine and phenelzine.",
"    </p>",
"    <p>",
"     The MAO inhibitors are usually not a first choice for the treatment of depression, but they may be especially effective for the treatment of atypical depression and depression that does not respond to other drugs. Side effects of MAO inhibitors may include dizziness, dry mouth, gastrointestinal upset, difficulty urinating, headache, unpredictable muscle contractions, and afternoon fatigue.",
"    </p>",
"    <p>",
"     People who take MAO inhibitors for depression must avoid foods and beverages that contain tyramine. These include fermented cheeses; beer; Chianti and some other wines; champagne; soy sauces; avocados; bananas; overripe or spoiled food; and any fermented, smoked, or aged fish or meat. People who accidentally consume tyramine while taking MAO inhibitors may experience severe high blood pressure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Trazodone",
"     </span>",
"     &nbsp;&mdash;&nbsp;Trazodone is a drug that is sometimes used to treat depression. However, it is not clear if it is as effective as other antidepressant drugs. As a result, trazodone is usually not a first choice for the treatment of depression.",
"    </p>",
"    <p>",
"     The most common side effect of trazodone is sedation; other side effects may include lightheadedness upon standing and nausea. A rare but potentially serious side effect of trazodone is irregular heart beat and priapism (a persistent erection that requires medical treatment).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      OTHER TREATMENT OPTIONS FOR DEPRESSION",
"     </span>",
"    </p>",
"    <p>",
"     Several other treatment options may alleviate depression in some people.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      St. John's wort",
"     </span>",
"     &nbsp;&mdash;&nbsp;St. John's wort (Hypericum perforatum) appears to alter levels of several neurochemicals in the brain. Studies suggest that for the treatment of mild depression, St. John's wort is more effective than a placebo and as effective as tricyclic antidepressants, with fewer side effects [",
"     <a class=\"abstract\" href=\"UTD.htm?21/24/21894/abstract/3\">",
"      3",
"     </a>",
"     ]. However, the long-term effectiveness of St. John's wort is unknown.",
"    </p>",
"    <p>",
"     St. John's wort is not approved by the United States Food and Drug Administration for the treatment of depression. Because the composition of St. John's wort products varies widely, some products may be less effective than others for relieving depression. The products that are most likely to be effective are those that are standardized at 0.3 percent hypericin. The dose in most studies is 300 mg three times per day, although doses as low as 250 mg twice per day may be effective.",
"    </p>",
"    <p>",
"     The side effects of St. John's wort may include stomach upset, dizziness or confusion, tiredness, and dry mouth. Rarely, some people who take St. John's wort notice that their skin becomes extremely sensitive to sunlight. The long-term safety of St. John's wort is unknown.",
"    </p>",
"    <p>",
"     It is important to tell your clinician if you use St. John's wort. This herb can reduce the effectiveness of drugs used to treat a variety of other medical conditions, including hormonal methods of birth control (eg, pills). Of particular concern are interactions with medications used to treat HIV and cancer. In general, patients on chemotherapy or antiviral therapy for HIV should not take St. John's wort. Furthermore, St. John's wort",
"     <strong>",
"      should not be used",
"     </strong>",
"     in combination with other antidepressants, particularly the selective serotonin reuptake inhibitors (SSRIs).",
"    </p>",
"    <p>",
"     Studies suggest that pregnant or breast-feeding women should not take St. John's wort. There are some concerns that the herb may lower fertility. St. John's wort is inappropriate for people with severe depression who are at risk for suicide.",
"    </p>",
"    <p>",
"     A good source for updated information about St. John's wort is the National Center for Complementary and Alternative Medicine, a branch of the National Institutes of Health (",
"     <a class=\"external\" href=\"file://www.nccam.nih.gov/health/stjohnswort/\">",
"      www.nccam.nih.gov/health/stjohnswort/",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Electroconvulsive therapy (ECT)",
"     </span>",
"     &nbsp;&mdash;&nbsp;During electroconvulsive therapy (ECT), an electrical current is passed through the brain, triggering a seizure. For unknown reasons, the seizure helps to restore the normal balance of neurochemicals in the brain. ECT is especially effective for people with depression who also have delusions (powerful, irrational beliefs) and for people who have severe depression despite maximal drug therapy. ECT can be used in pregnant women or in persons who cannot tolerate antidepressant medications, and is especially useful in persons who need a rapid-onset antidepressant treatment. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=see_link\">",
"      \"Medical consultation for electroconvulsive therapy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Patients who undergo ECT are given general anesthesia to induce sleep and prevent discomfort. Patients are monitored carefully before, during, and after the treatment. Side effects of this therapy include brief confusion and memory loss. Although ECT has been negatively portrayed in the media, this therapy often provides rapid and dramatic relief of depression and has very few side effects. Most people who undergo ECT find it a helpful treatment for their depression.",
"    </p>",
"    <p>",
"     More detailed information about ECT is available on the American Psychiatric Association's Web site,",
"     <a class=\"external\" href=\"file://www.psych.org/\">",
"      file://www.psych.org",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Repetitive transcranial magnetic stimulation (rTMS)",
"     </span>",
"     &nbsp;&mdash;&nbsp;During repetitive transcranial magnetic stimulation (rTMS), a powerful magnetic field is used to stimulate the brain. This therapy does not require anesthesia or cause any confusion or memory loss. The effectiveness of rTMS for the treatment of depression is still being studied.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exercise can improve depressive symptoms, although the effects occur more slowly than with antidepressant drugs. Although one study found that the depression-relieving benefit of exercise was equal to that of a selective serotonin reuptake inhibitor (SSRI) after 16 weeks [",
"     <a class=\"abstract\" href=\"UTD.htm?21/24/21894/abstract/4\">",
"      4",
"     </a>",
"     ], a review of multiple studies in patients with clinically significant depressive symptoms found only a short-term mild benefit of exercise on depression with limited evidence of a long term effect [",
"     <a class=\"abstract\" href=\"UTD.htm?21/24/21894/abstract/5\">",
"      5",
"     </a>",
"     ] .",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Light therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Light therapy can relieve the depression of seasonal affective disorder (SAD), which typically occurs during the winter months. Seasonal affective disorder is discussed separately. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22936?source=see_link\">",
"      \"Seasonal affective disorder\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Light therapy is usually done with a specially designed light box. The usual dose of light therapy is 10,000 lux, beginning with one 10 to 15 minute session per day, gradually increasing to 30 to 45 minutes per day depending upon response. It may take four to six weeks of light therapy to see a response, although some patients improve within days. Therapy is continued until sufficient daily light exposure is available through other sources, typically from springtime sun.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      ANTIDEPRESSANTS AND PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     Women who are taking antidepressants and considering pregnancy should talk with their healthcare provider. A woman who takes an antidepressant and discovers she is pregnant should not stop her medication suddenly. Instead, she should speak with her healthcare provider to determine whether she should continue, change to another medication, or slowly taper her medication.",
"    </p>",
"    <p>",
"     The decision to take an antidepressant during pregnancy is difficult because of the potential risks to the mother (if she is not treated or undertreated), her developing baby, and her family. All of the risks and benefits should be discussed with a knowledgeable and experienced healthcare provider, who can help to decide which treatment, if any, is best.",
"    </p>",
"    <p>",
"     Issues to consider include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Paroxetine has been associated with an increased risk of birth defects in babies whose mothers took the drug during the first 13 weeks of pregnancy",
"      </li>",
"      <li>",
"       Infants of women who took SSRIs during the last 13 weeks of pregnancy have an increased risk of temporary behavior changes. These behavior changes can include tremors or a slightly increased breathing rate, but rarely include more serious problems. Behavior changes usually disappear one to two weeks after birth.",
"      </li>",
"      <li>",
"       Exposure to tricyclic antidepressants can also cause temporary behavior changes in newborns. If a TCA is required, desipramine and nortriptyline are preferred due to fewer side effects in the fetus.",
"      </li>",
"      <li>",
"       In some but not all studies, SSRIs have also been associated with an increased risk of a serious lung problem called persistent pulmonary hypertension of the newborn. The risk is probably small and needs to be considered along with the potentially greater risk to the fetus and mother if the mother's depression is untreated.",
"      </li>",
"      <li>",
"       Monoamine oxidase inhibitors (MAOIs) (eg, phenelzine, tranylcypromine) are",
"       <strong>",
"        not",
"       </strong>",
"       recommended for use in pregnant women because animal studies have shown that MAOI exposure may limit the fetus's growth; there are insufficient data to know if MAOIs have the same effect in humans.",
"      </li>",
"      <li>",
"       Other antidepressant medications (eg, trazodone, bupropion, mirtazapine) are not recommended as a first-line depression treatment because long-term safety data are not available",
"      </li>",
"      <li>",
"       There have been no reports of long-term developmental or behavioral problems in children who were exposed to antidepressants during their mother's pregnancy",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H865949021\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6664824\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42146?source=see_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=see_link\">",
"      Patient information: Medicines for depression (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37106?source=see_link\">",
"      Patient information: Electroconvulsive therapy (ECT) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/45/8914?source=see_link\">",
"      Patient information: Post-traumatic stress disorder (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/9/41105?source=see_link\">",
"      Patient information: Postpartum depression (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/18/11554?source=see_link\">",
"      Patient information: When you have depression and another health problem (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/482?source=see_link\">",
"      Patient information: Serotonin syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6664896\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H865949028\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29735?source=see_link\">",
"      Depression in pregnant women: Clinical features and consequences",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=see_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=see_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"      Overview of psychosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=see_link\">",
"      Postpartum psychosis: Epidemiology, clinical manifestations, and assessment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29670?source=see_link\">",
"      Treatment of postpartum psychosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22936?source=see_link\">",
"      Seasonal affective disorder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=see_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Mental Health",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nimh.nih.gov/\">",
"      www.nimh.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Psychiatric Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.psych.org/\">",
"      www.psych.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Psychological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.apa.org/\">",
"      www.apa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Child and Adolescent Psychiatry",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aacap.org/\">",
"      www.aacap.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Depression and Bipolar Support Alliance (DBSA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"      www.DBSAlliance.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Foundation For Depressive Illness",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.depression.org/\">",
"      www.depression.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Mental Health Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nmha.org/\">",
"      www.nmha.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Alliance on Mental Illness",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nami.org/\">",
"      www.nami.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?21/24/21894/abstract/1-4,6,7\">",
"      1-4,6,7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?21/24/21894?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21894/abstract/1\">",
"      Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998; 280:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21894/abstract/2\">",
"      Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 2000; 132:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21894/abstract/3\">",
"      Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ 2000; 321:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21894/abstract/4\">",
"      Blumenthal JA, Babyak MA, Moore KA, et al. Effects of exercise training on older patients with major depression. Arch Intern Med 1999; 159:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21894/abstract/5\">",
"      Krogh J, Nordentoft M, Sterne JA, Lawlor DA. The effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2011; 72:529.",
"     </a>",
"    </li>",
"    <li>",
"     Depression Guideline Panel. Depression in Primary Care: Treatment of Major Depression: Clinical Practice Guideline. US Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR publication 93-0551, Rockville, MD 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21894/abstract/7\">",
"      Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology 2007; 32:2479.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f21_24_21894=[""].join("\n");
var outline_f21_24_21894=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DEPRESSION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PREVENTING SUICIDE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ANTIDEPRESSANTS VERSUS PSYCHOTHERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           PSYCHOTHERAPY TO TREAT DEPRESSION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           ANTIDEPRESSANT MEDICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           CHOICE OF ANTIDEPRESSANTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           OTHER TREATMENT OPTIONS FOR DEPRESSION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           ANTIDEPRESSANTS AND PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?42/3/43069\" title=\"table 1\">",
"           Antidepressant side eff PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f21_24_21895="Overview of hereditary neuropathies";
var content_f21_24_21895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hereditary neuropathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/24/21895/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21895/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/24/21895/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21895/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21895/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/24/21895/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21895/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/24/21895/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hereditary peripheral neuropathies have been classified based upon clinical characteristics, mode of inheritance, electrophysiologic features, metabolic defect, and subsequently upon specific genetic markers. The primary hereditary neuropathies predominantly or exclusively affect peripheral nerves and produce symptoms of peripheral nerve dysfunction. Other hereditary neuropathies affect both the central and peripheral nervous systems and, in some cases, other organs; in such patients, symptoms related to the peripheral neuropathy may be overshadowed by other manifestations of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the primary hereditary neuropathies were designated by eponyms that had the connotation of specific clinical features (eg, Charcot-Marie-Tooth disease or Dejerine-Sottas disease). However, phenotypic variability resulted in substantial diagnostic confusion. The Dyck classification developed in the 1970s helped to define specific types based upon clinical and electrophysiologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many of the primary hereditary neuropathies were divided into motor-sensory and sensory&ndash;autonomic neuropathies.",
"     </li>",
"     <li>",
"      The motor-sensory category was subdivided into types one through seven and the sensory neuropathies into types one through five. Many of these types were further divided into subcategories.",
"     </li>",
"     <li>",
"      Additional primary inherited neuropathies not included in this classification include hereditary neuropathy with pressure palsy, hereditary brachial plexopathy, and giant axonal neuropathy. The molecular defects in many of the inherited neuropathies have been identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will provide an overview of the hereditary neuropathies. Detailed discussions of the hereditary motor and sensory neuropathies, the hereditary sensory and autonomic neuropathies, and the hereditary neuropathies associated with generalized disorders are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link\">",
"     \"Hereditary sensory and autonomic neuropathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link\">",
"     \"Hereditary neuropathies associated with generalized disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEREDITARY MOTOR AND SENSORY NEUROPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main entity in this category, hereditary motor and sensory neuropathy (HMSN), also known as Charcot-Marie-Tooth (CMT) disease, is reviewed here briefly and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CMT is really a spectrum of disorders caused by specific mutations in one of several myelin genes that result in defects in myelin structure, maintenance, and formation. Each gene locus serves a specific function in maintaining myelin integrity. In addition to gene mutation, the clinical expression of these conditions is affected by \"gene dosage imbalance\" caused by DNA duplications or deletions. The association of different mutations within the same gene with various clinical phenotypes is a common finding in the",
"    <span class=\"nowrap\">",
"     HMSN/CMT",
"    </span>",
"    group of peripheral neuropathies. This variability suggests that these disorders represent a spectrum of related phenotypes caused by an underlying defect in peripheral nervous system myelination.",
"   </p>",
"   <p>",
"    CMT has been classified as types one through seven and consists of at least 30 different disorders. The major division comprises type 1 and type 2, which together are the most common hereditary peripheral neuropathies, with an estimated prevalence of 40 per 100,000. Common features include both motor and sensory nerve manifestations with distal leg weakness, foot deformities (pes cavus, hammer toes), and sensory deficits (",
"    <a class=\"graphic graphic_table graphicRef72688 graphicRef52711 \" href=\"UTD.htm?37/12/38094\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     HMSN/CMT 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;HMSN type 1, a demyelinating disorder of peripheral nerves, is also known as Charcot-Marie-Tooth type 1 (CMT1) disease. CMT1 is characterized by moderately to severely reduced nerve conduction velocity and onion bulb formation. It has been subdivided on the basis of genetic markers into types 1A, 1B, and 1C, with type 1A being most common, although the clinical manifestations are similar. Affected patients typically present in the first or early second decade, but infants may be symptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link&amp;anchor=H3#H3\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\", section on 'HMSN/CMT 1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early complaints may include frequent sprained ankles caused by distal muscle weakness or difficulty running and keeping up with peers. The only obvious physical findings may be loss of reflexes. Distal muscle atrophy often develops later and eventually causes atrophy of the intrinsic hand and foot muscles with calf muscle atrophy (the classic \"stork leg deformity\"), pes cavus, and hammer toes.",
"   </p>",
"   <p>",
"    Walking often is clumsy because of both muscle weakness and sensory loss. Sensory loss is gradual and mainly involves proprioception and vibration.",
"   </p>",
"   <p>",
"    Later changes include atrophy of the intrinsic hand and foot muscles. Palpable enlargement of the peripheral nerves may occur secondary to nerve hypertrophy. Ambulation is variable but usually is maintained through life. Life expectancy is not affected.",
"   </p>",
"   <p>",
"    The Roussy-Levy syndrome is a",
"    <span class=\"nowrap\">",
"     HMSN/CMT",
"    </span>",
"    type 1 phenotype that includes postural tremor and gait ataxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     HMSN/CMT 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;HMSN type 2 (CMT2, also called axonal CMT) is characterized by normal or mildly reduced nerve conduction velocity with decreased amplitude and axonal degenerative loss without hypertrophic features; demyelination with onion bulb formation does not occur or is minimal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\", section on 'HMSN/CMT 2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classic features of CMT2 include distal weakness, atrophy, sensory loss, decreased deep tendon reflexes and, less consistently, foot deformity. The onset of symptoms usually is in the second or third decade of life. The clinical course is similar to that of CMT1, but sensory symptoms typically predominate over motor symptoms, and peripheral nerves are not palpably enlarged. Distal trophic ulcerations in the feet may occur.",
"   </p>",
"   <p>",
"    A less common early onset form of CMT2 becomes clinically apparent before the child reaches five years of age. Weakness progresses rapidly, with loss of strength below the knees by the second decade. Ambulation often is lost by the time the child reaches mid-teens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     X-linked CMT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are X-linked dominant and X-linked recessive forms of CMT Type 1 and Type 2 involving different loci. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link&amp;anchor=H9#H9\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\", section on 'X-linked CMT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CMTX1, the X-linked dominant form of CMT Type 1, is the second most common form of CMT after CMT1A (see",
"    <a class=\"local\" href=\"#H5\">",
"     'HMSN/CMT 1'",
"    </a>",
"    above). Both sexes are affected, but symptoms are more prominent in males. Patients become symptomatic in the second decade and present with gait difficulties. Reflexes are lost at the ankles in all cases, whereas patellar reflexes are retained in about 50 percent of females. Demyelination and axonal loss histologically occurs, but onion bulb formation is minimal.",
"   </p>",
"   <p>",
"    There are a number of rare X-linked recessive forms of HMSN, including CMTX2, CMTX3, and Cowchock syndrome (CMT with deafness and mental retardation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HMSN/CMT 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two disorders, Dejerine-Sottas syndrome and congenital hypomyelinating neuropathy, have been classified as HMSN 3. The HMSN type 3 disorders are severe, early onset peripheral neuropathies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link&amp;anchor=H11#H11\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\", section on 'HMSN/CMT 3'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On histologic examination, patients with Dejerine-Sottas syndrome have thin myelin sheaths and large onion bulb formation, whereas those with congenital hypomyelinating neuropathy show essentially absent myelin without evidence of inflammation, myelin breakdown, or onion bulbs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     HMSN/CMT 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;HMSN type 4 was originally applied to Refsum disease, which now is characterized as a disorder of peroxisomal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H13#H13\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Refsum disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type 4 currently is used to classify the rapidly expanding heterogeneous group of autosomal recessive demyelinating motor sensory neuropathies (CMT4). The autosomal recessive forms are rare, clinically more severe, and less likely to result from mutations in structural myelin proteins than the autosomal dominant forms.",
"   </p>",
"   <p>",
"    Several subtypes of autosomal recessive",
"    <span class=\"nowrap\">",
"     HMSN/CMT",
"    </span>",
"    disease are known based upon electrophysiologic, pathologic, and genetic criteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link&amp;anchor=H14#H14\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\", section on 'CMT 4'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other HMSN/CMT types",
"    </span>",
"    &nbsp;&mdash;&nbsp;HMSN 5 refers to patients with autosomal dominant spastic paraparesis with sensory neuropathy. HMSN 6 refers to patients with dominant or recessive optic atrophy and motor sensory neuropathy. HMSN 7 refers to patients with retinitis pigmentosa and motor sensory neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link&amp;anchor=H23#H23\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\", section on 'HMSN/CMT 5, 6, and 7'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dominant intermediate Charcot-Marie-Tooth (DI-CMT) is an uncommon CMT variant characterized by intermediate nerve conduction velocities and both axonal and demyelinating features on histology. DI-CMT appears to be genetically heterogeneous, with autosomal dominant inheritance linked to several different loci. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link&amp;anchor=H10#H10\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\", section on 'Dominant intermediate CMT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HEREDITARY NEUROPATHY WITH LIABILITY TO PRESSURE PALSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary neuropathy with liability to pressure palsy (HNPP, tomaculous neuropathy) is a recurrent, episodic demyelinating neuropathy (",
"    <a class=\"graphic graphic_table graphicRef61436 \" href=\"UTD.htm?35/61/36827\">",
"     table 2",
"    </a>",
"    ). Affected patients typically present with isolated nerve palsies with localization in areas frequently affected by compression or trauma. Symptoms first appear in the second decade in most patients, but they can occur in younger children or be delayed until into the third decade [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Single nerve palsies typically appear sequentially, resolving in days to months, and then are followed by a motor deficit in the same or in another distribution.",
"   </p>",
"   <p>",
"    The most frequently affected nerves are those at common sites of trauma or entrapment and include the axillary, median, radial, ulnar, peroneal, or brachial plexus nerves. Other findings include cranial nerve involvement, nerve deafness, and scoliosis. In one series of 70 patients, nerve involvement in episodes of palsy occurred with the following frequencies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peroneal nerve &mdash; 36 percent",
"     </li>",
"     <li>",
"      Ulnar nerve &mdash; 28 percent",
"     </li>",
"     <li>",
"      Brachial plexus &mdash; 20 percent",
"     </li>",
"     <li>",
"      Radial nerve &mdash; 13 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Central nervous system white matter lesions have been reported in isolated patients and several members of a large family with HNPP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrophysiologic studies show a distinctive sensorimotor neuropathy pattern that can help to establish the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. A generalized sensory neuropathy with slowed conduction velocity and prolongation of distal motor latencies occurs. Motor conduction velocity is slowed only mildly, and F-wave latencies are prolonged. These changes are indicative of disproportionate slowing of distal nerve conduction. A superimposed but independent entrapment neuropathy with focal slowing at sites of compression with acute weakness also occurs.",
"   </p>",
"   <p>",
"    Sural nerve biopsy shows focal myelin thickening (tomacula) on light microscopy. These lesions are best seen with teased fiber preparations and appear as enlarged sausage-shaped thickenings of the myelin sheath [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HNPP is an autosomal dominant disorder associated in approximately 80 percent of cases with a 1.5 Mb deletion in chromosome 17p11.2 that results in reduced expression of the peripheral myelin protein 22 (PMP22) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/3,8-10\">",
"     3,8-10",
"    </a>",
"    ]. The deletion corresponds to the duplicated region present in most patients with Charcot-Marie-Tooth disease type 1A (see",
"    <a class=\"local\" href=\"#H5\">",
"     'HMSN/CMT 1'",
"    </a>",
"    above). Approximately 20 percent of patients with HNPP have point mutations or small deletions in the PMP22 gene, and sporadic cases with de novo deletions have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/3,10-12\">",
"     3,10-12",
"    </a>",
"    ]. Molecular genetic testing is available for confirmation of the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HEREDITARY BRACHIAL PLEXOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary brachial plexopathy (MIM 162100), also known as hereditary neuralgic amyotrophy (HNA), is reviewed here briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H18#H18\">",
"     \"Brachial plexus syndromes\", section on 'Hereditary brachial plexopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary brachial plexopathy is a rare autosomal dominant disorder characterized by recurrent, painful brachial plexopathies. The condition is caused by mutations in the SEPT9 gene. Hereditary brachial plexopathy is distinct from hereditary neuropathy with predisposition to pressure palsies (HNPP) discussed above (",
"    <a class=\"graphic graphic_table graphicRef61436 \" href=\"UTD.htm?35/61/36827\">",
"     table 2",
"    </a>",
"    ). Childhood onset of hereditary brachial plexopathy is not unusual. Many patients exhibit a relapsing-remitting course characterized by attacks that resolve spontaneously, either completely or incompletely, leaving additive residual weakness. The disorder can also follow a progressive pattern. Physical exertion and pregnancy are reported triggering events.",
"   </p>",
"   <p>",
"    Attacks are heralded by pain and paresthesias, followed by paresis of the shoulder and arm. While any nerve in the brachial plexus can be involved, injury to the upper part of the brachial plexus is most frequent. Characteristic somatic features of hereditary brachial plexopathy include short stature, hypotelorism, a small face, unusual skin folds, and creases on the neck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HEREDITARY SENSORY AND AUTONOMIC NEUROPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary sensory autonomic neuropathies (HSAN) are discussed here briefly and reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link\">",
"     \"Hereditary sensory and autonomic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The HSANs occur much less frequently than do the primary hereditary motor sensory neuropathies. The major feature of these conditions is loss of large myelinated and unmyelinated fibers. They have been categorized into types one through five, although some children do not fit well into this classification (",
"    <a class=\"graphic graphic_table graphicRef67377 \" href=\"UTD.htm?36/19/37180\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HSAN type I is the most common form of HSAN. It is characterized by degeneration of dorsal root ganglion and motor neurons, leading to distal sensory loss and later distal muscle wasting and weakness and variable neural deafness. Bone necrosis and spontaneous distal amputation can occur. Symptoms often begin in early childhood but may be delayed until the third decade. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'HMSN/CMT 1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms in HSAN type 2 are caused also by loss of pain, temperature, pressure and touch sensation with large and small fiber sensory involvement. Recurrent infections of the digits and fractures occur in early childhood, and mutilation of the fingers and toes occurs as the disease progresses. A stable, nonprogressive congenital form also has been recognized. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'HMSN/CMT 2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSAN type 3 is more commonly known as Riley-Day syndrome or familial dysautonomia. This disorder is a progressive sensorimotor neuropathy, but sympathetic autonomic dysfunction is responsible for most clinical manifestations. Neuropathic symptoms include loss of reflexes, hypotonia, and decreased perception of pain and temperature. Sympathetic symptoms include orthostatic hypotension, swallowing dysfunction, gastrointestinal motility dysfunction, bladder dysfunction, decreased or absent tearing, pupil dilation, decreased sweating (leading to defective temperature dysregulation), and blotchy skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN3 (Familial dysautonomia)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HSAN type 4, also called congenital insensitivity to pain with anhidrosis (CIPA), is an autosomal recessive disorder. Symptoms begin early in infancy and prominent features include profound loss of pain sensitivity, leading to injuries, self-mutilation, and osteomyelitis, episodic hyperthermia that can be associated with seizures, and mild to moderate mental retardation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H13#H13\">",
"       \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN4'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with HSAN type 5 disease have loss of pain and temperature sensation, but other sensation is preserved. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H14#H14\">",
"       \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN5'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GIANT AXONAL NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant axonal neuropathy (GAN) is a severe degenerative disorder of the peripheral nerves and central nervous system that becomes clinically apparent in early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. It is transmitted as an autosomal recessive trait [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/15\">",
"     15",
"    </a>",
"    ]. The disease locus maps to 16q24.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/16\">",
"     16",
"    </a>",
"    ], and the mutated GAN gene encodes for a cytoskeletal protein called gigaxonin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/17\">",
"     17",
"    </a>",
"    ]. Abnormal gigaxonin is presumed to be responsible for the generalized disorganization of cytoskeletal intermediate filaments [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected children present with a mixed motor sensory polyneuropathy, and distal limb weakness caused by the neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/21\">",
"     21",
"    </a>",
"    ]. A characteristic physical appearance is a hallmark of the disorder. The hair tends to be red and kinky, the forehead high, the complexion pale, and eyelashes long. Manifestations of central nervous system involvement include mental retardation, ataxia, nystagmus, spasticity, and optic atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Progressive gait deterioration occurs, with death usually by late adolescence.",
"   </p>",
"   <p>",
"    Nerve conduction studies are consistent with an axonal neuropathy. Electroencephalograms, visual evoked potentials, and somatosensory evoked responses also are abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/23\">",
"     23",
"    </a>",
"    ]. Brain MRI typically demonstrates subcortical, periventricular and cerebellar white matter lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis typically is made by nerve biopsy, which shows axonal loss and distortion of fibers by giant axonal swellings filled with densely packed bundles of neurofilaments [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/13,19,24\">",
"     13,19,24",
"    </a>",
"    ]. Similar filaments are seen in other tissues such as Schwann cells, fibroblasts, and vascular endothelium, findings that are consistent with a defect in intermediate filament organization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/19\">",
"     19",
"    </a>",
"    ]. Cerebral white matter shows leukoencephalopathy, and the cerebellum and optic tracts show atrophy with gliosis. The hair contains abnormal longitudinal grooves [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/24\">",
"     24",
"    </a>",
"    ]. Molecular genetic testing for mutations in the GAN gene is available [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21895/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NEUROPATHIES ASSOCIATED WITH GENERALIZED DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of generalized hereditary disorders are associated with neuropathy. Many of these disorders affect both the central and peripheral nervous systems and, in some cases, other organs. Symptoms related to the peripheral neuropathy may be overshadowed by other manifestations of the disease. A partial list of these disorders includes infantile neuroaxonal dystrophy, Tangier disease, abetalipoproteinemia, Refsum disease, Chediak-Higashi syndrome, and hereditary tyrosinemia.",
"   </p>",
"   <p>",
"    In addition, neuropathy is associated with a number of lysosomal storage diseases (eg, Fabry disease, Krabbe disease, metachromatic leukodystrophy, Niemann-Pick disease), mitochondrial disorders (eg, Leigh syndrome, Leber hereditary optic neuropathy), and DNA repair disorders (eg, xeroderma pigmentosum, Cockayne syndrome).",
"   </p>",
"   <p>",
"    The neuropathies associated with these generalized metabolic disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link\">",
"     \"Hereditary neuropathies associated with generalized disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/59/24497?source=see_link\">",
"       \"Patient information: Charcot-Marie-Tooth disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10539093\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary motor and sensory neuropathy (also known as Charcot-Marie-Tooth disease or CMT) is really a spectrum of disorders caused by specific mutations in one of several myelin genes that result in defects in myelin structure, maintenance, and formation. They have been classified as types 1 through 7 and include at least 30 different disorders (",
"      <a class=\"graphic graphic_table graphicRef72688 graphicRef52711 \" href=\"UTD.htm?37/12/38094\">",
"       table 1A-B",
"      </a>",
"      ). The major division comprises CMT1 and CMT 2, which together are the most frequent hereditary peripheral neuropathies. Shared features of CMT1 and CMT2 include both motor and sensory nerve manifestations with distal leg weakness, foot deformities (pes cavus, hammer toes), and sensory deficits. There are also X-linked dominant and X-linked recessive forms of CMT1 and CMT2 involving different loci. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hereditary motor and sensory neuropathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hereditary neuropathy with liability to pressure palsy (HNPP, tomaculous neuropathy) is a recurrent, episodic demyelinating neuropathy (",
"      <a class=\"graphic graphic_table graphicRef61436 \" href=\"UTD.htm?35/61/36827\">",
"       table 2",
"      </a>",
"      ). Affected patients typically present with isolated nerve palsies with localization in areas frequently affected by compression or trauma. Symptoms first appear in the second decade in most patients, but they can occur in younger children or be delayed until into the third decade. Single nerve palsies typically appear sequentially, resolving in days to months, and then are followed by a motor deficit in the same or in another distribution. The most frequently affected nerves are those at common sites of trauma or entrapment and include the axillary, median, radial, ulnar, peroneal, or brachial plexus nerves. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hereditary neuropathy with liability to pressure palsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hereditary brachial plexopathy is a rare autosomal dominant disorder characterized by recurrent, painful brachial plexopathies (",
"      <a class=\"graphic graphic_table graphicRef61436 \" href=\"UTD.htm?35/61/36827\">",
"       table 2",
"      </a>",
"      ). Many patients exhibit a relapsing-remitting course characterized by attacks that resolve spontaneously, either completely or incompletely, leaving additive residual weakness. The disorder can also follow a progressive pattern. Physical exertion and pregnancy are reported triggering events. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hereditary brachial plexopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hereditary sensory autonomic neuropathies (HSAN) occur much less frequently than do the primary hereditary motor sensory neuropathies. The major feature of these conditions is loss of large myelinated and unmyelinated fibers. They have been categorized into types one through five, although some children do not fit well into this classification (",
"      <a class=\"graphic graphic_table graphicRef67377 \" href=\"UTD.htm?36/19/37180\">",
"       table 3",
"      </a>",
"      ). HSAN type I is the most common form. It is characterized by degeneration of dorsal root ganglion and motor neurons, leading to distal sensory loss and later distal muscle wasting and weakness and variable neural deafness. Bone necrosis and spontaneous distal amputation can occur. Symptoms often begin in early childhood but may be delayed until the third decade. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hereditary sensory and autonomic neuropathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Giant axonal neuropathy is a severe degenerative disorder of the peripheral nerves and central nervous system that becomes clinically apparent in early childhood. Affected children present with a mixed motor sensory polyneuropathy, and distal limb weakness. A characteristic physical appearance is a hallmark of the disorder. The hair tends to be red and kinky, the forehead high, the complexion pale, and eyelashes long. Manifestations of central nervous system involvement include mental retardation, ataxia, nystagmus, spasticity, and optic atrophy. Progressive gait deterioration occurs, with death usually by late adolescence. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Giant axonal neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dyck PJ. Neuronal atrophy and degeneration predominantly affecting peripheral sensory and autonomic neurons. In: Peripheral Neuropathy, Dyck PJ, Thomas PK, Lambert EH, et al (Eds), WB Saunders, Philadelphia 1984. Vol 2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/2\">",
"      Gabre&euml;ls-Festen AA, Gabre&euml;ls FJ, Joosten EM, et al. Hereditary neuropathy with liability to pressure palsies in childhood. Neuropediatrics 1992; 23:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/3\">",
"      Mouton P, Tardieu S, Gouider R, et al. Spectrum of clinical and electrophysiologic features in HNPP patients with the 17p11.2 deletion. Neurology 1999; 52:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/4\">",
"      Sanahuja J, Franco E, Rojas-Garc&iacute;a R, et al. Central nervous system involvement in hereditary neuropathy with liability to pressure palsies: description of a large family with this association. Arch Neurol 2005; 62:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/5\">",
"      Tackenberg B, M&ouml;ller JC, Rindock H, et al. CNS involvement in hereditary neuropathy with pressure palsies (HNPP). Neurology 2006; 67:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/6\">",
"      Andersson PB, Yuen E, Parko K, So YT. Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. Neurology 2000; 54:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/7\">",
"      Meier C, Moll C. Hereditary neuropathy with liability to pressure palsies. Report of two families and review of the literature. J Neurol 1982; 228:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/8\">",
"      St&ouml;gbauer F, Young P, Kuhlenb&auml;umer G, et al. Hereditary recurrent focal neuropathies: clinical and molecular features. Neurology 2000; 54:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/9\">",
"      Mariman EC, Gabre&euml;ls-Festen AA, van Beersum SE, et al. Prevalence of the 1.5-Mb 17p deletion in families with hereditary neuropathy with liability to pressure palsies. Ann Neurol 1994; 36:650.",
"     </a>",
"    </li>",
"    <li>",
"     Bird TD. Hereditary neuropathy with liability to pressure palsies. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1392/ (Accessed on December 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/11\">",
"      Li J, Ghandour K, Radovanovic D, et al. Stoichiometric alteration of PMP22 protein determines the phenotype of hereditary neuropathy with liability to pressure palsies. Arch Neurol 2007; 64:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/12\">",
"      Infante J, Garc&iacute;a A, Combarros O, et al. Diagnostic strategy for familial and sporadic cases of neuropathy associated with 17p11.2 deletion. Muscle Nerve 2001; 24:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/13\">",
"      Carpenter S, Karpati G, Andermann F, Gold R. Giant axonal neuropathy. A clinically and morphologically distinct neurological disease. Arch Neurol 1974; 31:312.",
"     </a>",
"    </li>",
"    <li>",
"     Kuhlenb&auml;umer G, Timmerman V. Giant axonal neuropathy. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1136/ (Accessed on December 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/15\">",
"      Takebe Y, Koide N, Takahashi G. Giant axonal neuropathy: report of two siblings with endocrinological and histological studies. Neuropediatrics 1981; 12:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/16\">",
"      Ben Hamida C, Cavalier L, Belal S, et al. Homozygosity mapping of giant axonal neuropathy gene to chromosome 16q24.1. Neurogenetics 1997; 1:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/17\">",
"      Bomont P, Cavalier L, Blondeau F, et al. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet 2000; 26:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/18\">",
"      Flanigan KM, Crawford TO, Griffin JW, et al. Localization of the giant axonal neuropathy gene to chromosome 16q24. Ann Neurol 1998; 43:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/19\">",
"      Mohri I, Taniike M, Yoshikawa H, et al. A case of giant axonal neuropathy showing focal aggregation and hypophosphorylation of intermediate filaments. Brain Dev 1998; 20:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/20\">",
"      Mussche S, De Paepe B, Smet J, et al. Proteomic analysis in giant axonal neuropathy: new insights into disease mechanisms. Muscle Nerve 2012; 46:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/21\">",
"      Demir E, Bomont P, Erdem S, et al. Giant axonal neuropathy: clinical and genetic study in six cases. J Neurol Neurosurg Psychiatry 2005; 76:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/22\">",
"      Dooley JM, Oshima Y, Becker LE, Murphy EG. Clinical progression of giant-axonal neuropathy over a twelve year period. Can J Neurol Sci 1981; 8:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/23\">",
"      Majnemer A, Rosenblatt B, Watters G, Andermann F. Giant axonal neuropathy: central abnormalities demonstrated by evoked potentials. Ann Neurol 1986; 19:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21895/abstract/24\">",
"      Treiber-Held S, Budjarjo-Welim H, Reimann D, et al. Giant axonal neuropathy: a generalized disorder of intermediate filaments with longitudinal grooves in the hair. Neuropediatrics 1994; 25:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6207 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21895=[""].join("\n");
var outline_f21_24_21895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10539093\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEREDITARY MOTOR AND SENSORY NEUROPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HMSN/CMT 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HMSN/CMT 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      X-linked CMT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HMSN/CMT 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HMSN/CMT 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other HMSN/CMT types",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HEREDITARY NEUROPATHY WITH LIABILITY TO PRESSURE PALSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HEREDITARY BRACHIAL PLEXOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HEREDITARY SENSORY AND AUTONOMIC NEUROPATHIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GIANT AXONAL NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NEUROPATHIES ASSOCIATED WITH GENERALIZED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10539093\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6207\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6207|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/37/39517\" title=\"table 1A\">",
"      CMT types 1 through 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/3/16445\" title=\"table 1B\">",
"      CMT types 4 through 7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/61/36827\" title=\"table 2\">",
"      HNPP and hereditary brachial plexopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/19/37180\" title=\"table 3\">",
"      Clinical features HSAN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/59/24497?source=related_link\">",
"      Patient information: Charcot-Marie-Tooth disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_24_21896="Common pathoanatomical conditions of the lumbar spine";
var content_f21_24_21896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Common pathoanatomical conditions of the lumbar spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 623px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) A superior view of a normal lumbar vertebra with cauda equina, nerve roots, intervertebral disc and ligamentum flavum.",
"    <br>",
"     (B) A superior view demonstrating abnormalities including a thickened ligamentum flavum, a hypertrophied facet and a herniated disc. These pathological structures cause the canal to narrow and can impinge on the cauda equina and nerve roots.",
"     <br>",
"      (C) A lateral view of the lumbosacral spine demonstrating spondylolysis and spondylolisthesis. Spondylolysis is a fracture in the pars interarticularis of the vertebra. Spondylolisthesis occurs when this fracture widens and the vertebral body slides forward on the one below it.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21896=[""].join("\n");
var outline_f21_24_21896=null;
var title_f21_24_21897="Cholangioscopy and pancreatoscopy";
var content_f21_24_21897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cholangioscopy and pancreatoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/24/21897/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21897/contributors\">",
"     Raj J Shah, MD, FASGE, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/24/21897/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21897/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/24/21897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21897/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/24/21897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miniature endoscopes and catheters have been developed that permit direct visualization of the bile and pancreatic ducts (collectively known as cholangiopancreatoscopy). These endoscopes and catheters are passed through the working channel of a duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).",
"   </p>",
"   <p>",
"    The first optical choledochoscope was described in 1941 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/1\">",
"     1",
"    </a>",
"    ], and the per oral approach was subsequently introduced in the early 1970's [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Continued refinements have resulted in commercially available small-diameter cholangiopancreatoscopes that include working channels and the ability to deflect the tip of the scope [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review cholangioscopy and pancreatoscopy performed during ERCP using commercially available instruments. ERCP and alternate approaches for direct bile duct visualization are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18166?source=see_link\">",
"     \"Percutaneous transhepatic cholangioscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341530894\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangioscopy is primarily used for the treatment of difficult bile duct stones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64197 \" href=\"UTD.htm?1/4/1093\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53961 \" href=\"UTD.htm?10/24/10626\">",
"     picture 1",
"    </a>",
"    ) and for the evaluation of indeterminate biliary strictures (ie, strictures that could not be diagnosed as being benign or malignant with sampling techniques such as brush cytology or biopsy) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78679 \" href=\"UTD.htm?21/60/22468\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61451 \" href=\"UTD.htm?38/27/39348\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79883 \" href=\"UTD.htm?8/31/8690\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50986 \" href=\"UTD.htm?23/5/23632\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61611 \" href=\"UTD.htm?22/27/22960\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/6-15\">",
"     6-15",
"    </a>",
"    ]. During cholangioscopy, targeted biopsies of bile duct lesions can be obtained (",
"    <a class=\"graphic graphic_picture graphicRef68712 \" href=\"UTD.htm?0/45/720\">",
"     picture 4",
"    </a>",
"    ). It can also be used to evaluate equivocal fluoroscopy findings during endoscopic retrograde cholangiopancreatography, to assess the extent of cholangiocarcinoma prior to surgery, and to identify of stones not seen by conventional cholangiography. In one series that included primary sclerosing cholangitis patients, 30 percent had stones that had been missed by cholangiography [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During cholangioscopy, bile duct stones can be fragmented using electrohydraulic or laser lithotripsy probes that are applied directly to the stones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=see_link\">",
"     \"Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similarly, pancreatoscopy is used in the evaluation of pancreatic strictures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52127 \" href=\"UTD.htm?36/53/37715\">",
"     image 5",
"    </a>",
"    ) and suspected intraductal mucinous neoplasms (IPMN) (",
"    <a class=\"graphic graphic_picture graphicRef62736 \" href=\"UTD.htm?3/29/3536\">",
"     picture 5",
"    </a>",
"    ) and for the treatment of main pancreatic duct stones (",
"    <a class=\"graphic graphic_picture graphicRef78620 \" href=\"UTD.htm?20/20/20815\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80055 \" href=\"UTD.htm?8/33/8720\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73476 \" href=\"UTD.htm?5/42/5794\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52479 \" href=\"UTD.htm?28/4/28740\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/6,13-16\">",
"     6,13-16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341533731\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systems available for cholangiopancreatoscopy include endoscope-based systems, commonly referred to as \"mother-daughter\" systems (Olympus America, Center Valley, PA and Pentax, Orangeburg, NY). There is also a catheter-based system (SpyGlass, Boston Scientific Endoscopy, Marlboro, MA). In addition, cholangiopancreatoscopy can be performed using a slim gastroscope in patients with a dilated common bile duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56909361\">",
"    <span class=\"h2\">",
"     Mother-daughter systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mother-daughter systems are comprised of a mother duodenoscope and a daughter cholangiopancreatoscope. The daughter scope is inserted through the accessory channel of the mother scope. Two endoscopists are required for mother-daughter systems. One endoscopist controls the mother scope, while the other controls the daughter scope. Daughter scopes range in diameter from 3.1 to 3.4 mm, with a working channel of 1.2 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/13\">",
"     13",
"    </a>",
"    ]. The tip of the daughter scope can be deflected up and down. Commercially available daughter scopes are fiberoptic, though high-resolution video daughter scope prototypes are being investigated. The 1.2 mm working channel permits passage of miniature biopsy forceps and intraductal lithotripsy fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56909368\">",
"    <span class=\"h2\">",
"     Catheter-based system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catheter-based system requires a single endoscopist for its operation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/18\">",
"     18",
"    </a>",
"    ]. The system includes a 0.77 mm optical probe which is passed through a 3.3 mm 4-lumen catheter. In addition to a lumen for the optical probe, the catheter includes a 1.2 mm working channel and two dedicated 0.6 mm irrigation channels. The tip of the catheter can be deflected in four directions (up-down and left-right).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56909375\">",
"    <span class=\"h2\">",
"     Slim gastroscopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slim gastroscopes can be used in patients with dilated common bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/13\">",
"     13",
"    </a>",
"    ]. Like catheter-based systems, only one endoscopist is required. Slim gastroscopes have diameters of 5 to 6 mm, and thus can only be used in patients with dilated common bile ducts. If a gastroscope is being used, insufflation should be with saline, water, or CO2, as air insufflation has been associated with air embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The advantage of using a slim gastroscope is that the video image quality is superior and may include narrow band imaging (NBI) capability (",
"    <a class=\"graphic graphic_picture graphicRef55989 \" href=\"UTD.htm?38/2/38945\">",
"     picture 9",
"    </a>",
"    ); the working channel is larger and can accommodate argon plasma coagulation (APC) probes, larger biopsy forceps, and lithotripsy fibers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341530902\">",
"    <span class=\"h1\">",
"     PATIENT PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341531002\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to endoscopic retrograde cholangiopancreatography (ERCP), patients typically take no food by mouth for four to eight hours and sometimes longer if there is known or suspected delayed gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/21\">",
"     21",
"    </a>",
"    ]. Alternatively, clear liquids can be taken up to two hours before elective procedures requiring general anesthesia or",
"    <span class=\"nowrap\">",
"     sedation/analgesia",
"    </span>",
"    (American Society of Anesthesiologists guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/22\">",
"     22",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341531009\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most medications can be continued up to the time of endoscopy and are usually taken with a small sip of water. Some medications may need to be adjusted prior to upper endoscopy, such as medications for diabetes, due to decreased oral intake around the time of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341531016\">",
"    <span class=\"h2\">",
"     Management of anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding the management of antiplatelet agents or anticoagulants must take into account the risk of bleeding engendered by maintaining the patient on the agent through the procedure and the risk of a thromboembolic event if the agent is discontinued in the periprocedural period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/23\">",
"     23",
"    </a>",
"    ]. Many patients undergoing cholangioscopy will require a sphincterotomy, which is considered to be a high-risk procedure with regard to bleeding (",
"    <a class=\"graphic graphic_table graphicRef50700 \" href=\"UTD.htm?43/43/44731\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341531023\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines regarding the use of antibiotics in patients undergoing endoscopic procedures do not specifically address antibiotic prophylaxis for cholangioscopy or pancreatoscopy. However, preprocedural antibiotic prophylaxis has generally been recommended for all patients due to a potentially higher rate of cholangitis when compared with those patients undergoing ERCP without cholangioscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/24\">",
"     24",
"    </a>",
"    ]. The antibiotic regimens used are the same as those used for other patients undergoing ERCP who require antibiotic prophylaxis (",
"    <a class=\"graphic graphic_table graphicRef54121 \" href=\"UTD.htm?13/60/14285\">",
"     table 2",
"    </a>",
"    ). Antibiotic prophylaxis is also recommended for pancreatoscopy, especially in the setting of obstructing pancreatic duct stones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341530910\">",
"    <span class=\"h2\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;General anesthesia or monitored-anesthesia care is typically utilized for patients undergoing cholangiopancreatoscopy because the procedure times are longer than for standard endoscopic retrograde cholangiopancreatography (ERCP), and fluid irrigation to enhance intraductal visualization can lead to pooling within the stomach, increasing the risk of aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407344\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341533965\">",
"    <span class=\"h3\">",
"     Scope insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangioscopy and pancreatoscopy are carried out during ERCP. Lesions and suspicious areas identified during cholangiography can be mapped with spot radiographs to aid with subsequent cholangioscopic localization. Sphincterotomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stricture dilation are performed as needed to facilitate scope passage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/17\">",
"     17",
"    </a>",
"    ]. Daughter cholangioscopes or catheter-based systems are passed through the working channel of a standard therapeutic duodenoscope. Following ERCP and guidewire access to the common bile duct or pancreatic duct, the cholangiopancreatoscope is advanced over the guidewire and into the duct using a combination of endoscopic and fluoroscopic guidance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75248 \" href=\"UTD.htm?0/60/965\">",
"     image 7",
"    </a>",
"    ). If a slim gastroscope is being used, it may be inserted into the duct over a guidewire placed during ERCP or by way of a free-hand technique [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the scope is advanced to the target location, the guidewire (if used) is removed to enhance visualization and to permit use of the working channel.",
"   </p>",
"   <p>",
"    Factors that may complicate scope passage include narrow duct diameters and tight strictures. In addition, circumferential visualization may be compromised by the presence of a markedly dilated duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407351\">",
"    <span class=\"h3\">",
"     Intraductal lithotripsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrohydraulic lithotripsy (EHL) can be used to treat both bile duct (",
"    <a class=\"graphic graphic_picture graphicRef53961 \" href=\"UTD.htm?10/24/10626\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef54231 \" href=\"UTD.htm?12/13/12498\">",
"     picture 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63431 \" href=\"UTD.htm?15/23/15731\">",
"     image 8",
"    </a>",
"    ) and pancreatic duct stones. Cholangioscopic or pancreatoscopic visualization during intraductal lithotripsy helps to avoid duct injury. The EHL fiber contains two coaxially insulated electrodes ending at an open tip. During water immersion, sparks are generated that produce high-amplitude hydraulic pressure waves for stone fragmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/26\">",
"     26",
"    </a>",
"    ]. A generator produces a series of high-voltage electrical impulses at a frequency of 1 to 20 per second, with settings ranging from 50 to 100 volts. The tip of the EHL fiber should protrude no more than 2 to 3 mm from the scope and be positioned",
"    <em>",
"     en face",
"    </em>",
"    with the stone while the generator's foot pedal is depressed to deliver energy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=see_link\">",
"     \"Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative to EHL is pulsed laser lithotripsy. During laser lithotripsy, a laser beam is transmitted via a flexible quartz fiber through the working channel of the cholangiopancreatoscope (",
"    <a class=\"graphic graphic_picture graphicRef80055 \" href=\"UTD.htm?8/33/8720\">",
"     picture 7",
"    </a>",
"    ). The application of repetitive pulses of laser energy to the stone leads to the formation of a gaseous collection of ions and free electrons of high kinetic energy. This plasma rapidly expands as it absorbs the laser energy and then collapses, inducing a spherical mechanical shockwave between the laser fiber and stone, leading to stone fragmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407418\">",
"    <span class=\"h3\">",
"     Intraductal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two methods can be used to obtain targeted biopsies from the bile duct: cholangioscopy-directed biopsy and cholangioscopy-assisted biopsy. Cholangioscopy-directed biopsy is performed by passing a miniature cholangioscope biopsy forceps through the working channel, under direct endoscopic visualization.",
"   </p>",
"   <p>",
"    For cholangioscopy-assisted biopsy, the target biopsy site is localized using cholangioscopic visualization and fluoroscopic spot films of the cholangioscope tip positioned at the lesion. After removing the cholangioscope, a conventional biliary biopsy forceps is then passed through the working channel of the duodenoscope to obtain tissue samples under fluoroscopic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/10\">",
"     10",
"    </a>",
"    ]. For pancreatic duct biopsies, a similar method can be utilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407358\">",
"    <span class=\"h2\">",
"     Bile duct stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangioscopy with electrohydraulic lithotripsy (EHL) is associated with a high rate of success for removal of extrahepatic biliary stones that have failed extraction with conventional endoscopic retrograde cholangiopancreatography (ERCP) techniques. Clearance rates of 83 to 100 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/8,9,28\">",
"     8,9,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=see_link&amp;anchor=H4#H4\">",
"     \"Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective series of 94 patients with difficult biliary stones reported that 90 percent achieved stone clearance after one or two EHL sessions [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/9\">",
"       9",
"      </a>",
"      ]. Failure of stone clearance occurred in 11 patients. Reasons for failure included difficult stone location (four patients), stricturing below the stones (two patients), poor patient health status precluding additional interventions (one patient), failure of stone clearance requiring common bile duct exploration (one patient), and failure to remove a stone due to a broken cholangioscope. Five of the patients with failed stone clearance had stones in the common hepatic or intrahepatic ducts. Complications were seen in 17 percent of patients and included cholangitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      jaundice, hemobilia, pancreatitis, bile leaks, and bradycardia.",
"     </li>",
"     <li>",
"      A 100 percent clearance rate with no complications was reported in a study that included 26 patients who underwent EHL [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/28\">",
"       28",
"      </a>",
"      ]. Twelve of the patients had had a prior attempt at mechanical lithotripsy. In the remaining 14, mechanical lithotripsy had not been attempted because the stones were intrahepatic (four patients), because a stricture was present (six patients), because the stones were in the cystic duct (two patients), or because the stones were impacted in the common bile duct (two patients). Mechanical lithotripsy was not reattempted according to the study protocol, which may explain the high clearance rate compared with other series.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited and older studies have compared EHL or laser lithotripsy with extracorporeal shock wave lithotripsy (ESWL), in which stones are fragmented using shock waves that are directed through the body onto the stone(s). With the increased availability of cholangioscopy, ESWL for biliary stones is not utilized as ERCP is still required to remove stone fragments (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10168?source=see_link&amp;anchor=H10#H10\">",
"     \"Extracorporeal shock wave lithotripsy for pancreatic stones\", section on 'Application of shock waves'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A non-randomized comparison of 118 patients who underwent ESWL or per oral cholangioscopy with EHL revealed similar stone clearance rates in the ESWL and EHL groups (79 versus 74 percent, p&gt;0.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <sup>",
"      </sup>",
"      The disadvantage in the ESWL group was the necessity to perform ERCP to extract stone fragments. Cross-over treatments resulted in successful duct clearance in 94 percent of patients.",
"     </li>",
"     <li>",
"      In a randomized prospective study of 60 patients, cholangioscopy-guided laser lithotripsy demonstrated a significantly higher rate of duct clearance (97 versus 73 percent) and a lower number of lithotripsy sessions (1.2 versus 3) compared with ESWL [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/30\">",
"       30",
"      </a>",
"      ]. Following cross-over therapy, 59 out of 60 (98 percent) achieved duct clearance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intrahepatic bile duct stones (seen in the setting of recurrent pyogenic cholangitis) require more intensive endotherapy than extrahepatic stones. One study reported 36 consecutive patients with hepatolithiasis treated with per oral cholangioscopy-directed EHL or laser lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/31\">",
"     31",
"    </a>",
"    ]. Despite a mean of 4.5 cholangioscopy sessions and adjunctive ESWL in one-third of the patients, ductal clearance was achieved in only 75 percent (64 percent complete, 11 percent partial). After a mean of 7.8 years of follow-up, symptomatic recurrence developed in 22 and 25 percent of those with complete and partial clearance, respectively. In general, effective treatment of hepatolithiasis may require combined per oral and percutaneous approaches or surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14472?source=see_link&amp;anchor=H12#H12\">",
"     \"Recurrent pyogenic cholangitis\", section on 'Prevention of long-term complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407365\">",
"    <span class=\"h2\">",
"     Mirizzi syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stone extraction has also been successful in patients with Mirizzi syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/33\">",
"     33",
"    </a>",
"    ]. Long-term success appears to be most likely in patients who do not have residual gallbladder stones [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44565?source=see_link&amp;anchor=H9#H9\">",
"     \"Mirizzi syndrome\", section on 'Endoscopic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407372\">",
"    <span class=\"h2\">",
"     Pancreatic stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Completely or partially obstructing pancreatic duct stones causing an increase in intraductal pressure are implicated as a cause of chronic abdominal pain in patients with chronic pancreatitis. Either alone or as an adjunct to ESWL, per oral pancreatoscopy-guided lithotripsy may permit duct clearance. Small case series of intraoperative EHL followed by decompressive surgery (n = 10) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/35\">",
"     35",
"    </a>",
"    ] and EHL plus ESWL (n = 6) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/36\">",
"     36",
"    </a>",
"    ] revealed complete main duct clearance rates of 100 and 50 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10168?source=see_link\">",
"     \"Extracorporeal shock wave lithotripsy for pancreatic stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=see_link&amp;anchor=H5#H5\">",
"     \"Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones\", section on 'Pancreatic stones'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not routinely employ ESWL in the treatment of pancreatic stones. In a preliminary report of our experience with 45 patients with pancreatic duct stones, a total of 121 ERCPs were performed, of which 83 (74 percent) included peroral pancreatoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/37\">",
"     37",
"    </a>",
"    ]. Complete duct clearance using an endoscope-based pancreatoscopy system was achieved in 21 of 31 patients (68 percent). In patients treated with catheter-based pancreatoscopy systems, complete clearance was achieved in 8 of 14 (57 percent). In the 39 patients for whom follow-up information was available, clinical improvement at a median follow-up of 15 months was seen in 77 percent of patients treated with endoscope-based systems and in 100 percent of patients treated with catheter-based systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407380\">",
"    <span class=\"h2\">",
"     Suspected biliary malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with indeterminate strictures or filling defects at cholangiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73203 \" href=\"UTD.htm?34/37/35411\">",
"     image 9",
"    </a>",
"    ), cholangioscopy permits direct inspection of the epithelium for subtle abnormalities or to obtain biopsies (",
"    <a class=\"graphic graphic_picture graphicRef50986 \" href=\"UTD.htm?23/5/23632\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61611 \" href=\"UTD.htm?22/27/22960\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60577 \" href=\"UTD.htm?40/8/41089\">",
"     picture 11",
"    </a>",
"    ). However, stent-associated changes and trauma related to stricture dilation may alter the mucosal appearance, making visual diagnosis more challenging.",
"   </p>",
"   <p>",
"    The sensitivity of conventional brush cytology or biopsy during ERCP for detecting malignancy in most series ranges from 30 to 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/38-65\">",
"     38-65",
"    </a>",
"    ]. Cholangioscopic visualization may enhance diagnosis by detecting \"tumor vessels\" (irregularly dilated and tortuous blood vessels) in the setting of malignancy (",
"    <a class=\"graphic graphic_picture graphicRef73222 \" href=\"UTD.htm?23/20/23872\">",
"     picture 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55989 \" href=\"UTD.htm?38/2/38945\">",
"     picture 9",
"    </a>",
"    ). In addition, the presence of intraductal nodules or masses, infiltrative or ulcerated strictures, or papillary or villous mucosal projections may indicate malignancy and should prompt biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/66\">",
"     66",
"    </a>",
"    ]. A combination of tumor vessels plus percutaneous biopsy diagnosed 96 percent of cancers in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/67\">",
"     67",
"    </a>",
"    ]. Tumor vessels were not present in histologically benign strictures, as determined by one-year follow-up.",
"   </p>",
"   <p>",
"    Prospective single-center case series using either endoscope-based or catheter-based systems have shown that cholangioscopic visualization with or without biopsy has a sensitivity of 89 to 100 percent and a specificity of 79 to 96 percent for detecting biliary malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/10,12,68,69\">",
"     10,12,68,69",
"    </a>",
"    ]. When biopsies are obtained during cholangioscopy, tissue confirmation for malignancy is achieved in 57 to 82 percent of patients with a final diagnosis of malignancy (based on surgical resection or clinical follow-up) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/10,12,40,68-70\">",
"     10,12,40,68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an international, multicenter observational series utilizing catheter-based cholangioscopy for indeterminate pancreaticobiliary pathology and difficult stone disease, 226 patients underwent cholangioscopic inspection, 86 percent having previously undergone at least one prior ERCP. Of the cohort, 140 underwent cholangioscopy-directed biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/71\">",
"     71",
"    </a>",
"    ]. Complete ERCP, cholangioscopic, and biopsy data were available for a subset of 95 patients. The sensitivities and specificities of ERCP, cholangioscopic visualization, and cholangioscopy-directed tissue biopsies for detecting malignancy were 51 and 54 percent, 78 and 82 percent, and 49 and 98 percent, respectively.",
"   </p>",
"   <p>",
"    Confirming malignancy in the sclerotic-type of cholangiocarcinoma can be difficult because malignant cells are often absent on superficial mucosal biopsies as the result of a fibrotic reaction to the tumor and expansion into the subepithelial layers.",
"   </p>",
"   <p>",
"    Although not commercially available, video cholangioscopy has been combined with narrow band imaging at select referral centers in Japan and the US, and the addition of this technology may enhance mucosal and tumor vessel visualization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407388\">",
"    <span class=\"h2\">",
"     Primary sclerosing cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of malignancy in primary sclerosing cholangitis (PSC) is difficult using only cholangiography or tissue sampling. In a prospective study of 53 patients with PSC, adding direct visualization with cholangioscopy increased the diagnostic yield compared with ERCP alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/74\">",
"     74",
"    </a>",
"    ]. Twelve patients (23 percent) had cancer, and 41 (77 percent) had benign disease. Compared with cholangiography, cholangioscopy had significantly better sensitivity (92 versus 66 percent), specificity (93 versus 51 percent), and negative predictive value (97 versus 84 percent). However, this yield has not been duplicated by other centers including our own, and traditional malignant features seen on cholangioscopy, such as nodular and infiltrative strictures, may be present in benign PSC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407395\">",
"    <span class=\"h2\">",
"     Suspected pancreatic neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the relatively narrow caliber and tortuous segments of the pancreatic duct, intraductal inspection may be limited compared with examining the biliary tree. Per oral pancreatoscopy can define the extent and provide a histopathological diagnosis for intraductal papillary mucinous neoplasia (IPMN) and other pancreatic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/75\">",
"     75",
"    </a>",
"    ]. For IPMN, determining the presence of main pancreatic duct lesions is important, as the risk of high-grade dysplasia or malignancy is higher than with side-branch lesions alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In distinguishing benign from malignant IPMN, the endoscopic visualization of fish egg-like projections with prominent vasculature, villous, and vegetative protrusions correlates with malignant lesions, with a sensitivity and specificity of 68 and 87 percent, respectively, with lower sensitivity for branch-type compared with main duct lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/77\">",
"     77",
"    </a>",
"    ]. Several studies have compared per oral pancreatoscopy with intraductal ultrasound (IDUS), computed tomography (CT), endoscopic ultrasound (EUS), and pancreatography for distinguishing benign from malignant IPMN lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/77-81\">",
"     77-81",
"    </a>",
"    ]. The finding of 3 to 4 mm projections on pancreatoscopy of main duct IPMN lesions has a sensitivity for malignancy of 67 to 100 percent, compared with 16 to 32 percent for CT, 56 to 100 percent for IDUS, and 55 to 92 percent for EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. A combination of pancreatoscopy and IDUS may improve the ability to identify the longitudinal and transmural spread of pancreatic malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33353?source=see_link\">",
"     \"Intraductal ultrasound of the pancreaticobiliary ductal system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the evaluation of pancreatic strictures, a study that included 115 patients with a minimum two-year follow-up found that pancreatoscopy detected 63 percent of pancreatic cancers, 80 percent of benign strictures, and 95 percent of IPMN lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/82\">",
"     82",
"    </a>",
"    ]. Neoplasia assessment was based upon the presence of coarse mucosa, submucosal protrusion, friability, tumor vessels, and papillary projections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407403\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with per oral cholangioscopy and pancreatoscopy are often associated with specific maneuvers performed during endoscopic retrograde cholangiopancreatography (ERCP; eg, sphincterotomy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link&amp;anchor=H84322341#H84322341\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications specific to the performance of cholangiopancreatoscopy include cholangitis, which is related to intraductal fluid irrigation, pancreatitis in the setting of pancreatoscopy, and, uncommonly, hemobilia and bile leaks attributable to intraductal lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/6,9,24,83\">",
"     6,9,24,83",
"    </a>",
"    ]. Our center retrospectively assessed patients undergoing ERCP with or without cholangiopancreatoscopy and found that ERCP with cholangiopancreatoscopy may be associated with a significantly higher rate of procedure-related complications than ERCP alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/24\">",
"     24",
"    </a>",
"    ]. This increased risk was observed in overall complications (7.0 versus 2.9 percent), consensus complications (pancreatitis, perforation, cholangitis, or bleeding; 4.2 versus 2.2 percent), and specifically with post-procedural cholangitis (1.0 versus 0.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21897/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953407410\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Miniature endoscopes and catheters have been developed that permit direct visualization of the bile and pancreatic ducts (cholangioscopy and pancreatoscopy, respectively). These endoscopes and catheters are passed through the working channel of a standard therapeutic duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cholangioscopy with intraductal lithotripsy has become an established modality in the treatment of difficult biliary stones. When used in the evaluation of indeterminate biliary strictures by endoscopists experienced in recognizing intraductal pathology, it increases the diagnostic yield of tissue sampling. (See",
"      <a class=\"local\" href=\"#H341530894\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H953407358\">",
"       'Bile duct stones'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H953407380\">",
"       'Suspected biliary malignancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pancreatoscopy is complementary to other imaging modalities in the evaluation of intraductal papillary mucinous neoplasms of the pancreas and is emerging as a sole or adjunctive therapy to extracorporeal shock wave lithotripsy for the treatment of main pancreatic duct stones. It remains investigational in the diagnosis of pancreatic adenocarcinoma. (See",
"      <a class=\"local\" href=\"#H341530894\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H953407372\">",
"       'Pancreatic stones'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H953407395\">",
"       'Suspected pancreatic neoplasms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications specific to the performance of cholangiopancreatoscopy include cholangitis, which is related to intraductal fluid irrigation, pancreatitis in the setting of pancreatoscopy, and, uncommonly, hemobilia and bile leaks attributable to intraductal lithotripsy. (See",
"      <a class=\"local\" href=\"#H953407403\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/1\">",
"      McIver MA. An instrument for visualizing the interior of the common duct at operation. Surgery 1941; 9:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/2\">",
"      Kawai K, Nakajima M, Akasaka Y, et al. [A new endoscopic method: the peroral choledocho-pancreatoscopy (author's transl)]. Leber Magen Darm 1976; 6:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/3\">",
"      Vennes JA, Silvis SE. Endoscopic visualization of bile and pancreatic ducts. Gastrointest Endosc 1972; 18:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/4\">",
"      Urakami Y, Seifert E, Butke H. Peroral direct cholangioscopy (PDCS) using routine straight-view endoscope: first report. Endoscopy 1977; 9:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/5\">",
"      Soda K, Shitou K, Yoshida Y, et al. Peroral cholangioscopy using new fine-caliber flexible scope for detailed examination without papillotomy. Gastrointest Endosc 1996; 43:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/6\">",
"      ASGE Technology Committee, Shah RJ, Adler DG, et al. Cholangiopancreatoscopy. Gastrointest Endosc 2008; 68:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/7\">",
"      Ponchon T, Chavaillon A, Ayela P, Lambert R. Retrograde biliary ultrathin endoscopy enhances biopsy of stenoses and lithotripsy. Gastrointest Endosc 1989; 35:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/8\">",
"      Piraka C, Shah RJ, Awadallah NS, et al. Transpapillary cholangioscopy-directed lithotripsy in patients with difficult bile duct stones. Clin Gastroenterol Hepatol 2007; 5:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/9\">",
"      Arya N, Nelles SE, Haber GB, et al. Electrohydraulic lithotripsy in 111 patients: a safe and effective therapy for difficult bile duct stones. Am J Gastroenterol 2004; 99:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/10\">",
"      Shah RJ, Langer DA, Antillon MR, Chen YK. Cholangioscopy and cholangioscopic forceps biopsy in patients with indeterminate pancreaticobiliary pathology. Clin Gastroenterol Hepatol 2006; 4:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/11\">",
"      Awadallah NS, Chen YK, Piraka C, et al. Is there a role for cholangioscopy in patients with primary sclerosing cholangitis? Am J Gastroenterol 2006; 101:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/12\">",
"      Fukuda Y, Tsuyuguchi T, Sakai Y, et al. Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. Gastrointest Endosc 2005; 62:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/13\">",
"      Nguyen NQ, Binmoeller KF, Shah JN. Cholangioscopy and pancreatoscopy (with videos). Gastrointest Endosc 2009; 70:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/14\">",
"      Jung M, Zipf A, Schoonbroodt D, et al. Is pancreatoscopy of any benefit in clarifying the diagnosis of pancreatic duct lesions? Endoscopy 1998; 30:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/15\">",
"      Iqbal S, Stevens PD. Cholangiopancreatoscopy for targeted biopsies of the bile and pancreatic ducts. Gastrointest Endosc Clin N Am 2009; 19:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/16\">",
"      Sasahira N, Isayama H, Nagano R, et al. Noncalcified pancreatic stone treated with electrohydraulic lithotripsy using SpyGlass pancreatoscopy. Endoscopy 2011; 43 Suppl 2 UCTN:E272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/17\">",
"      Shah RJ, Chen YK. Transpapillary and percutaneous choledochoscopy in the evaluation and management of biliary strictures and stones. Techniques in Gastrointest Endosc 2007; 9:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/18\">",
"      Chen YK, Pleskow DK. SpyGlass single-operator peroral cholangiopancreatoscopy system for the diagnosis and therapy of bile-duct disorders: a clinical feasibility study (with video). Gastrointest Endosc 2007; 65:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/19\">",
"      Larghi A, Waxman I. Endoscopic direct cholangioscopy by using an ultra-slim upper endoscope: a feasibility study. Gastrointest Endosc 2006; 63:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/20\">",
"      Albert JG, Friedrich-Rust M, Elhendawy M, et al. Peroral cholangioscopy for diagnosis and therapy of biliary tract disease using an ultra-slim gastroscope. Endoscopy 2011; 43:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/21\">",
"      Faigel DO, Eisen GM, Baron TH, et al. Preparation of patients for GI endoscopy. Gastrointest Endosc 2003; 57:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/22\">",
"      American Society of Anesthesiologists Committee. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology 2011; 114:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/23\">",
"      Eisen GM, Baron TH, Dominitz JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002; 55:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/24\">",
"      Sethi A, Chen YK, Austin GL, et al. ERCP with cholangiopancreatoscopy may be associated with higher rates of complications than ERCP alone: a single-center experience. Gastrointest Endosc 2011; 73:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/25\">",
"      Brauer BC, Sethi A, Shah RJ, et al. Direct cholangioscopy by free-hand cannulation for diagnosis and therapy of biliary diseases. Gastrointest Endosc 2008; 67:AB148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/26\">",
"      Sievert CE Jr, Silvis SE. Evaluation of electrohydraulic lithotripsy as a means of gallstone fragmentation in a canine model. Gastrointest Endosc 1987; 33:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/27\">",
"      Hochberger J, Gruber E, Wirtz P, et al. Lithotripsy of gallstones by means of a quality-switched giant-pulse neodymium:yttrium-aluminum-garnet laser. Basic in vitro studies using a highly flexible fiber system. Gastroenterology 1991; 101:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/28\">",
"      Farrell JJ, Bounds BC, Al-Shalabi S, et al. Single-operator duodenoscope-assisted cholangioscopy is an effective alternative in the management of choledocholithiasis not removed by conventional methods, including mechanical lithotripsy. Endoscopy 2005; 37:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/29\">",
"      Adamek HE, Maier M, Jakobs R, et al. Management of retained bile duct stones: a prospective open trial comparing extracorporeal and intracorporeal lithotripsy. Gastrointest Endosc 1996; 44:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/30\">",
"      Neuhaus H, Zillinger C, Born P, et al. Randomized study of intracorporeal laser lithotripsy versus extracorporeal shock-wave lithotripsy for difficult bile duct stones. Gastrointest Endosc 1998; 47:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/31\">",
"      Okugawa T, Tsuyuguchi T, K C S, et al. Peroral cholangioscopic treatment of hepatolithiasis: Long-term results. Gastrointest Endosc 2002; 56:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/32\">",
"      Lee SK, Seo DW, Myung SJ, et al. Percutaneous transhepatic cholangioscopic treatment for hepatolithiasis: an evaluation of long-term results and risk factors for recurrence. Gastrointest Endosc 2001; 53:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/33\">",
"      Binmoeller KF, Thonke F, Soehendra N. Endoscopic treatment of Mirizzi's syndrome. Gastrointest Endosc 1993; 39:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/34\">",
"      Tsuyuguchi T, Saisho H, Ishihara T, et al. Long-term follow-up after treatment of Mirizzi syndrome by peroral cholangioscopy. Gastrointest Endosc 2000; 52:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/35\">",
"      Craigie JE, Adams DB, Byme TK, et al. Endoscopic electrohydraulic lithotripsy in the management of pancreatobiliary lithiasis. Surg Endosc 1998; 12:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/36\">",
"      Howell DA, Dy RM, Hanson BL, et al. Endoscopic treatment of pancreatic duct stones using a 10F pancreatoscope and electrohydraulic lithotripsy. Gastrointest Endosc 1999; 50:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/37\">",
"      Attwell GA, Chen YK, Brauer BC, et al. ERCP with per oral pancreatoscopy for calcific chronic pancreatitis using endoscope and catheter-based pancreatoscopes: A 10 year single center experience. Gastrointest Endosc 2011; 73:AB121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/38\">",
"      Howell DA, Parsons WG, Jones MA, et al. Complete tissue sampling of biliary strictures at ERCP using a new device. Gastrointest Endosc 1996; 43:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/39\">",
"      De Bellis M, Sherman S, Fogel EL, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 1). Gastrointest Endosc 2002; 56:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/40\">",
"      Hartman DJ, Slivka A, Giusto DA, Krasinskas AM. Tissue yield and diagnostic efficacy of fluoroscopic and cholangioscopic techniques to assess indeterminate biliary strictures. Clin Gastroenterol Hepatol 2012; 10:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/41\">",
"      Kurzawinski TR, Deery A, Dooley JS, et al. A prospective study of biliary cytology in 100 patients with bile duct strictures. Hepatology 1993; 18:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/42\">",
"      Sch&ouml;fl R. Diagnostic endoscopic retrograde cholangiopancreatography. Endoscopy 2001; 33:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/43\">",
"      Trent V, Khurana KK, Pisharodi LR. Diagnostic accuracy and clinical utility of endoscopic bile duct brushing in the evaluation of biliary strictures. Arch Pathol Lab Med 1999; 123:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/44\">",
"      Lee JG, Leung JW, Baillie J, et al. Benign, dysplastic, or malignant--making sense of endoscopic bile duct brush cytology: results in 149 consecutive patients. Am J Gastroenterol 1995; 90:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/45\">",
"      Logrono R, Kurtycz DF, Molina CP, et al. Analysis of false-negative diagnoses on endoscopic brush cytology of biliary and pancreatic duct strictures: the experience at 2 university hospitals. Arch Pathol Lab Med 2000; 124:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/46\">",
"      Rumalla A, Baron TH, Leontovich O, et al. Improved diagnostic yield of endoscopic biliary brush cytology by digital image analysis. Mayo Clin Proc 2001; 76:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/47\">",
"      Pugliese V, Antonelli G, Vincenti M, Gatteschi B. Endoductal tissue sampling of biliary strictures through endoscopic retrograde cholangiopan creatography (ERCP). Tumori 1997; 83:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/48\">",
"      Schoefl R, Haefner M, Wrba F, et al. Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses. Scand J Gastroenterol 1997; 32:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/49\">",
"      Parasher VK, Huibregtse K. Endoscopic retrograde wire-guided cytology of malignant biliary strictures using a novel scraping brush. Gastrointest Endosc 1998; 48:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/50\">",
"      Fogel EL, Sherman S. How to improve the accuracy of diagnosis of malignant biliary strictures. Endoscopy 1999; 31:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/51\">",
"      Foutch PG. Diagnosis of cancer by cytologic methods performed during ERCP. Gastrointest Endosc 1994; 40:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/52\">",
"      Howell DA, Beveridge RP, Bosco J, Jones M. Endoscopic needle aspiration biopsy at ERCP in the diagnosis of biliary strictures. Gastrointest Endosc 1992; 38:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/53\">",
"      Mohandas KM, Swaroop VS, Gullar SU, et al. Diagnosis of malignant obstructive jaundice by bile cytology: results improved by dilating the bile duct strictures. Gastrointest Endosc 1994; 40:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/54\">",
"      Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al. Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999; 31:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/55\">",
"      Stewart CJ, Burke GM. Value of p53 immunostaining in pancreatico-biliary brush cytology specimens. Diagn Cytopathol 2000; 23:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/56\">",
"      Morales CP, Burdick JS, Saboorian MH, et al. In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies. Gastrointest Endosc 1998; 48:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/57\">",
"      Itoi T, Shinohara Y, Takeda K, et al. Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers. Gastrointest Endosc 2000; 52:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/58\">",
"      Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/59\">",
"      Saurin JC, Joly-Pharaboz MO, Pernas P, et al. Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures. Gut 2000; 47:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/60\">",
"      Ryan ME, Baldauf MC. Comparison of flow cytometry for DNA content and brush cytology for detection of malignancy in pancreaticobiliary strictures. Gastrointest Endosc 1994; 40:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/61\">",
"      Tamada K, Sugano K. Diagnosis and non-surgical treatment of bile duct carcinoma: developments in the past decade. J Gastroenterol 2000; 35:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/62\">",
"      Rumalla A, Petersen BT. Diagnosis and therapy of biliary tract malignancy. Semin Gastrointest Dis 2000; 11:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/63\">",
"      Bain VG, Abraham N, Jhangri GS, et al. Prospective study of biliary strictures to determine the predictors of malignancy. Can J Gastroenterol 2000; 14:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/64\">",
"      Pugliese V, Conio M, Nicol&ograve; G, et al. Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study. Gastrointest Endosc 1995; 42:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/65\">",
"      Sugiyama M, Atomi Y, Wada N, et al. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. Am J Gastroenterol 1996; 91:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/66\">",
"      Seo DW, Lee SK, Yoo KS, et al. Cholangioscopic findings in bile duct tumors. Gastrointest Endosc 2000; 52:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/67\">",
"      Kim HJ, Kim MH, Lee SK, et al. Tumor vessel: a valuable cholangioscopic clue of malignant biliary stricture. Gastrointest Endosc 2000; 52:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/68\">",
"      Ramchandani M, Reddy DN, Gupta R, et al. Role of single-operator peroral cholangioscopy in the diagnosis of indeterminate biliary lesions: a single-center, prospective study. Gastrointest Endosc 2011; 74:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/69\">",
"      Siddiqui AA, Mehendiratta V, Jackson W, et al. Identification of cholangiocarcinoma by using the Spyglass Spyscope system for peroral cholangioscopy and biopsy collection. Clin Gastroenterol Hepatol 2012; 10:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/70\">",
"      Draganov PV, Chauhan S, Wagh MS, et al. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. Gastrointest Endosc 2012; 75:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/71\">",
"      Chen YK, Parsi MA, Binmoeller KF, et al. Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). Gastrointest Endosc 2011; 74:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/72\">",
"      Itoi T, Sofuni A, Itokawa F, et al. Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos). Gastrointest Endosc 2007; 66:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/73\">",
"      Shah RJ, Chen YK. Video cholangiopancreatoscopy with narrow band imaging (NBI): Spectrum of mucosal and vascular patterns in patients with pancreaticobiliary pathology. Gastrointest Endosc 2009; 69:AB117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/74\">",
"      Tischendorf JJ, Kr&uuml;ger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 2006; 38:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/75\">",
"      Ringold DA, Shah RJ. Peroral pancreatoscopy in the diagnosis and management of intraductal papillary mucinous neoplasia and indeterminate pancreatic duct pathology. Gastrointest Endosc Clin N Am 2009; 19:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/76\">",
"      Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000; 24:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/77\">",
"      Hara T, Yamaguchi T, Ishihara T, et al. Diagnosis and patient management of intraductal papillary-mucinous tumor of the pancreas by using peroral pancreatoscopy and intraductal ultrasonography. Gastroenterology 2002; 122:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/78\">",
"      Mukai H, Yasuda K, Nakajima M. Differential diagnosis of mucin-producing tumors of the pancreas by intraductal ultrasonography and peroral pancreatoscopy. Endoscopy 1998; 30 Suppl 1:A99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/79\">",
"      Yasuda K, Sakata M, Ueda M, et al. The use of pancreatoscopy in the diagnosis of intraductal papillary mucinous tumor lesions of the pancreas. Clin Gastroenterol Hepatol 2005; 3:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/80\">",
"      Seo DW, Kim MH, Lee SK, et al. The value of pancreatoscopy in patients with mucinous ductal ectasia. Endoscopy 1997; 29:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/81\">",
"      Yamaguchi T, Hara T, Tsuyuguchi T, et al. Peroral pancreatoscopy in the diagnosis of mucin-producing tumors of the pancreas. Gastrointest Endosc 2000; 52:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/82\">",
"      Yamao K, Ohashi K, Nakamura T, et al. Efficacy of peroral pancreatoscopy in the diagnosis of pancreatic diseases. Gastrointest Endosc 2003; 57:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21897/abstract/83\">",
"      Binmoeller KF, Br&uuml;ckner M, Thonke F, Soehendra N. Treatment of difficult bile duct stones using mechanical, electrohydraulic and extracorporeal shock wave lithotripsy. Endoscopy 1993; 25:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 633 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.196.66.12-1617F87D8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21897=[""].join("\n");
var outline_f21_24_21897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H953407410\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341530894\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341533731\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56909361\">",
"      Mother-daughter systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56909368\">",
"      Catheter-based system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56909375\">",
"      Slim gastroscopes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341530902\">",
"      PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341531002\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341531009\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341531016\">",
"      Management of anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341531023\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341530910\">",
"      Sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H953407344\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H341533965\">",
"      - Scope insertion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H953407351\">",
"      - Intraductal lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H953407418\">",
"      - Intraductal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H953407358\">",
"      Bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H953407365\">",
"      Mirizzi syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H953407372\">",
"      Pancreatic stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H953407380\">",
"      Suspected biliary malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H953407388\">",
"      Primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H953407395\">",
"      Suspected pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H953407403\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H953407410\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/633\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/633|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/4/1093\" title=\"diagnostic image 1\">",
"      Cholangiogram cuboidal bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/60/22468\" title=\"diagnostic image 2\">",
"      Common hepatic duct stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/27/39348\" title=\"diagnostic image 3\">",
"      Stricture at the hepatic duct bifurcation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/31/8690\" title=\"diagnostic image 4\">",
"      Distal common bile duct stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/53/37715\" title=\"diagnostic image 5\">",
"      Pancreatogram suggesting mid-duct stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/4/28740\" title=\"diagnostic image 6\">",
"      Pancreatogram following stone removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/60/965\" title=\"diagnostic image 7\">",
"      Pancreatoscope on fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/23/15731\" title=\"diagnostic image 8\">",
"      Cholangiogram following stone clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/37/35411\" title=\"diagnostic image 9\">",
"      Common hepatic duct mass seen on cholangiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/633|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/24/10626\" title=\"picture 1\">",
"      Bile duct stone seen on cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/5/23632\" title=\"picture 2\">",
"      Ulcerated stricture on cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/27/22960\" title=\"picture 3\">",
"      Cholangiocarcinoma on cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/45/720\" title=\"picture 4\">",
"      Cholangioscopy-directed biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/29/3536\" title=\"picture 5\">",
"      IPMN pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/20/20815\" title=\"picture 6\">",
"      Pancreatic duct stone pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/33/8720\" title=\"picture 7\">",
"      Pancreatoscopy-directed stone fragmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/42/5794\" title=\"picture 8\">",
"      Pancreatic stone removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/2/38945\" title=\"picture 9\">",
"      NBI tumor vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/13/12498\" title=\"picture 10\">",
"      Cholangioscopy following electrohydraulic lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/8/41089\" title=\"picture 11\">",
"      Common hepatic duct mass on cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/20/23872\" title=\"picture 12\">",
"      Tumor vessels seen with white light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/633|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/43/44731\" title=\"table 1\">",
"      Bleeding risk GI procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/60/14285\" title=\"table 2\">",
"      Abx prophylaxis regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=related_link\">",
"      Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=related_link\">",
"      Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10168?source=related_link\">",
"      Extracorporeal shock wave lithotripsy for pancreatic stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33353?source=related_link\">",
"      Intraductal ultrasound of the pancreaticobiliary ductal system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=related_link\">",
"      Laser lithotripsy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44565?source=related_link\">",
"      Mirizzi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=related_link\">",
"      Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18166?source=related_link\">",
"      Percutaneous transhepatic cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14472?source=related_link\">",
"      Recurrent pyogenic cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_24_21898="New onset urticaria";
var content_f21_24_21898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   New onset urticaria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/24/21898/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21898/contributors\">",
"     Clifton O Bingham, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/24/21898/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21898/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21898/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/24/21898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/24/21898/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/24/21898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria, or hives, is a common disorder with a prevalence of approximately 20 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/1\">",
"     1",
"    </a>",
"    ]. A typical urticarial lesion is an intensely pruritic, erythematous plaque (",
"    <a class=\"graphic graphic_picture graphicRef78544 \" href=\"UTD.htm?6/47/6896\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72519 \" href=\"UTD.htm?29/2/29728\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63644 \" href=\"UTD.htm?23/55/24433\">",
"     picture 3",
"    </a>",
"    ). Urticaria is sometimes accompanied by angioedema, which is swelling deeper in the skin. A presumptive trigger, such as a drug, food ingestion, insect sting, or infection, may be identifiable in patients with new onset urticaria, although no specific cause is found in many cases, particularly when the condition persists for weeks or months. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Etiologies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, etiologies, diagnosis, and management of new onset urticaria will be reviewed here. Chronic urticaria and isolated angioedema are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"     \"Chronic urticaria: Standard management and patient education\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=see_link\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25448761\">",
"    <span class=\"h1\">",
"     CATEGORIZATION OF URTICARIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria (with or without angioedema) is commonly categorized by its chronicity:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25448768\">",
"    <span class=\"h2\">",
"     Acute urticaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria is considered acute when it has been present for less than six weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25448775\">",
"    <span class=\"h2\">",
"     Chronic urticaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria is considered chronic when it is recurrent, with signs and symptoms recurring most days of the week, for six weeks or longer.",
"   </p>",
"   <p>",
"    The period of six weeks is somewhat arbitrary and simply represents a time frame in which new cases of urticaria usually resolve. More than two-thirds of cases of new onset urticaria prove to be self-limited (acute) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/2\">",
"     2",
"    </a>",
"    ]. The lesions of acute and chronic urticaria are identical in appearance, so when the problem first develops, it is not possible to differentiate the two disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria affects up to 20 percent of the population at some point in their lives and occurs across the age spectrum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticarial lesions are circumscribed, raised, erythematous plaques, often with central pallor (",
"    <a class=\"graphic graphic_picture graphicRef78544 \" href=\"UTD.htm?6/47/6896\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63644 \" href=\"UTD.htm?23/55/24433\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81678 \" href=\"UTD.htm?11/2/11311\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81168 \" href=\"UTD.htm?22/0/22542\">",
"     picture 5",
"    </a>",
"    ). Lesions may be round, oval, or serpiginous in shape, and vary in size from less than a centimeter, to several centimeters in diameter (",
"    <a class=\"graphic graphic_picture graphicRef81678 \" href=\"UTD.htm?11/2/11311\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53590 \" href=\"UTD.htm?41/58/42912\">",
"     picture 6",
"    </a>",
"    ). They are intensely itchy. Pruritus may disrupt work, school, or sleep. Symptoms often seem most severe at night.",
"   </p>",
"   <p>",
"    Individual lesions usually appear and enlarge over the course of minutes to hours, and then disappear within 24 hours, without leaving residual ecchymotic marks on the skin unless there is trauma from scratching. Urticaria is not normally painful, and lesions that are painful or leave bruising at the site of the lesions should raise suspicion for urticarial vasculitis. (See",
"    <a class=\"local\" href=\"#H10818951\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Any area of the body may be affected, although areas in which clothing compresses the skin (ie, under waistbands) or skin rubs together (axillae) are sometimes affected more dramatically.",
"   </p>",
"   <p>",
"    Angioedema, when associated with urticaria, usually affects the face and lips, extremities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genitals. Angioedema WITHOUT urticaria, should prompt consideration of other angioedema disorders, such as drug-induced angioedema (eg, ACE inhibitors), idiopathic angioedema, and hereditary and acquired C1 inhibitor deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37465?source=see_link\">",
"     \"ACE inhibitor-induced angioedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria is mediated by cutaneous mast cells in the superficial dermis. Basophils have also been identified in lesional biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/4\">",
"     4",
"    </a>",
"    ]. Mast cells and basophils release multiple mediators upon activation, including histamine, which cause itching, and vasodilatory mediators, which cause localized swelling in the uppermost layers of the skin. Angioedema is the same process involving mast cells deeper in the dermis and subcutaneous tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link\">",
"     \"Mast cells: Development, identification, and physiologic roles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential causes of new onset urticaria are numerous, although no specific etiology can be identified in many patients. Acute urticaria is more likely to have an identifiable etiology, compared with chronic urticaria. The different etiologies activate mast cells through various mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818075\">",
"    <span class=\"h2\">",
"     Common causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common causes of new onset urticaria include infections, allergic reactions to medications, foods, or insect stings and bites, reactions to medications that cause nonallergic mast cell activation (eg, narcotics), and ingestion of nonsteroidal antiinflammatory medications (NSAIDs) (",
"    <a class=\"graphic graphic_table graphicRef54872 \" href=\"UTD.htm?15/35/15932\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral, bacterial, and parasitic infections are associated with new onset urticaria.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Viral and bacterial",
"      </strong>",
"      &mdash; Acute urticaria may develop during or following a viral or bacterial infection, particularly in children. Infections are associated with over 80 percent of cases of acute urticaria in some pediatric series [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/2,5,6\">",
"       2,5,6",
"      </a>",
"      ]. Immune activation, involving immune complex formation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complement activation are proposed mechanisms, although the exact pathogenesis is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study, common viral illnesses and bacterial infections (eg, urinary tract infections) were the leading identifiable trigger for acute urticaria in 57 children between the ages of one and three years who presented to an emergency department [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/5\">",
"       5",
"      </a>",
"      ]. Many of these children had also received antibiotics, so it was not clear in these patients if the infection, the drug, or the combination had triggered urticaria.",
"     </li>",
"     <li>",
"      In another study, 88 children presenting to an emergency department with delayed cutaneous reactions while taking beta-lactam antibiotics were evaluated. Of these, 47 of 88 had urticarial eruptions. All were tested for common childhood viral infections and then later evaluated for drug allergy with testing followed by drug challenge (regardless of test results) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/7\">",
"       7",
"      </a>",
"      ]. Two-thirds had one or more positive viral studies. When the children were later challenged with the culprit antibiotic, only four had recurrent urticaria. Thus, urticaria was related to the viral infection or the combination of the viral infection and the antibiotic in most, and only 4 of 88 had a drug allergy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1966239#H1966239\">",
"       \"Allergy to penicillins\", section on 'Delayed urticarial eruptions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute urticaria, refractory to antihistamines but responsive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      , has been associated with documented Mycoplasma pneumoniae infection in children [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute urticaria can occur in the prodromic, preicteric phase of hepatitis A or B infection, and less commonly with hepatitis C [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/10\">",
"       10",
"      </a>",
"      ]. Urticaria may be an initial manifestation of HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"       \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Parasitic infections",
"      </strong>",
"      &mdash; Parasitic infections generally cause acute, self-limited urticaria in association with prominent eosinophilia [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infections with Ancylostoma, Strongyloides, Filaria, Echinococcus, Trichinella, Toxocara, Fasciola, Schistosoma mansoni, and Blastocystis hominis have all been associated with urticaria. Stool examination is probably only indicated in travelers to endemic areas and to patients with peripheral blood eosinophilia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"       \"Approach to the patient with eosinophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ingestion of fish contaminated with the parasite Anisakis simplex can also cause urticaria. Anisakis can be transmitted through the ingestion of sushi [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/61/16346?source=see_link&amp;anchor=H19#H19\">",
"       \"Seafood allergies: Fish and shellfish\", section on 'Anisakis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     IgE-mediated allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated, type I immediate allergic reactions often involve urticaria. Urticaria that is caused by an allergic reaction usually occurs within minutes to two hours of exposure to the culprit allergen. Causes include medications, foods and food additives, insect stings and bites, latex, and blood products.",
"   </p>",
"   <p>",
"    Allergic reactions may be limited to the skin or part of a systemic allergic reaction (ie, anaphylaxis) (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64957 \" href=\"UTD.htm?35/20/36172\">",
"     table 3",
"    </a>",
"    ). Generalized urticaria or angioedema following exposure to a potential allergen should be interpreted as a systemic reaction with an attendant risk of anaphylaxis upon subsequent exposure and patients should be advised to avoid the potential cause until further evaluated. (See",
"    <a class=\"local\" href=\"#H10819030\">",
"     'Referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Medications",
"      </strong>",
"      &mdash; The antibiotics most frequently implicated in causing IgE-mediated urticaria include beta-lactams (penicillins and cephalosporins), although antibiotics from virtually all classes have been reported (",
"      <a class=\"graphic graphic_picture graphicRef75230 \" href=\"UTD.htm?27/16/27905\">",
"       picture 7",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"       \"Allergy to penicillins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Stinging and biting insects",
"      </strong>",
"      &mdash; Stinging insects that can cause true urticarial lesions, as part of an allergic reaction, include Hymenoptera (bees, wasps, or hornets and imported fire ants) and Triatoma (kissing bugs).",
"      <br/>",
"      <br/>",
"      Bedbugs, fleas, and mites can cause papular urticaria, usually on the lower extremities. The lesions of papular urticaria resolve over weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=see_link\">",
"       \"Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36615?source=see_link\">",
"       \"Reactions to bites from kissing bugs (Triatoma)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39286?source=see_link\">",
"       \"Bedbugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Latex",
"      </strong>",
"      &mdash; Occupational, recreational, dental, or surgical exposure to latex may cause urticaria, angioedema, asthma, or anaphylaxis in susceptible individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/14\">",
"       14",
"      </a>",
"      ]. Everyday scenarios in which patients may be exposed to significant amounts of latex include inflation of balloons and use of latex gloves. Penile and",
"      <span class=\"nowrap\">",
"       vulvar/vaginal",
"      </span>",
"      urticaria and angioedema are seen upon exposure to latex condoms, with",
"      <span class=\"nowrap\">",
"       vulvar/vaginal",
"      </span>",
"      symptoms resembling acute vaginitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9785?source=see_link\">",
"       \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Foods and certain food additives",
"      </strong>",
"      &mdash; Allergic reactions to foods can cause urticaria, typically within 30 minutes of ingestion. Milk, egg, peanuts, tree nuts, soy, and wheat are the most common foods to cause generalized urticaria in children. In adults, fish, shellfish, tree nuts, and peanuts are most often implicated [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"       \"Clinical manifestations of food allergy: An overview\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Synthetic additives in commercially prepared foods are believed to be a relatively rare cause of urticarial reactions. In contrast, certain natural compounds, such as the yellow food dye annatto and the red dye carmine red have been well-documented causes of urticaria and anaphylaxis. Adverse reactions to food additives are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=see_link\">",
"       \"Allergic and asthmatic reactions to food additives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Contact with allergens",
"      </strong>",
"      &mdash; Physical contact with a number of agents may result in urticaria, including plant products and resins, raw fruits and vegetables, or raw seafood. People employed in food processing can develop contact urticaria from various exposures [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/16\">",
"       16",
"      </a>",
"      ]. Children sometimes develop urticaria upon contact with animal saliva, if allergic to those allergens. In contrast, detergents, soaps, and lotions are more likely to cause contact dermatitis than urticaria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"       \"Overview of dermatitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=see_link\">",
"       \"Contact dermatitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Urticarial transfusion reactions",
"      </strong>",
"      &mdash; Acute urticaria in the setting of transfusion may arise from several mechanisms, including IgE-mediated allergic reactions, complement-mediated reactions, and other immunologic events. These reactions are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"       \"Immunologic blood transfusion reactions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Direct mast cell activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain drugs, foods, and plants can cause urticaria due to mast cell degranulation through a non-IgE mediated mechanism. The most frequently implicated are narcotics, muscle relaxants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , and radiocontrast medium. Some berries and nettle plants are examples of plants and plant foods that cause direct mast cell activation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Narcotics",
"      </strong>",
"      &mdash; Opiate analgesics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      , cause direct mast cell activation.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       Dextromethorphan",
"      </a>",
"      , an opiate derivative ingredient in cough suppressant syrups, can also cause urticaria [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Muscle relaxants",
"      </strong>",
"      &mdash; Anesthetic muscle relaxants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/14/6374?source=see_link\">",
"       atracurium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"       vecuronium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      , and curare may cause urticaria. Muscle relaxants can also cause IgE-mediated anaphylaxis. Allergic reactions to these medications are reviewed in greater detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link\">",
"       \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      &mdash; The \"Red man\" syndrome is seen after rapid vancomycin infusion and presents as diffuse erythema or flushing, sometimes with accompanying urticaria. The concomitant use of opiates and vancomycin may increase the likelihood of a reaction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link\">",
"       \"Vancomycin hypersensitivity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Radiocontrast medium",
"      </strong>",
"      &mdash; Radiocontrast agents are associated with urticaria and angioedema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=see_link\">",
"       \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Certain foods",
"      </strong>",
"      &mdash; Tomatoes, strawberries, and a small number of other foods can cause generalized urticaria or contact urticaria through nonimmunologic mechanisms, particularly in young children [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/6\">",
"       6",
"      </a>",
"      ]. These foods are sometimes referred to as \"pseudoallergens.\" IgE-mediated allergies to these foods are also possible.",
"     </li>",
"     <li>",
"      <strong>",
"       Stinging nettle",
"      </strong>",
"      &mdash; The nettle plant (Urtica dioica) after which the disorder \"urticaria\" was named, is a common weed found in Europe, North and South America, and parts of Africa, which causes hives and a stinging sensation immediately following contact with the skin [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. These symptoms may be due to histamine in the nettle plant itself, in addition to mediators that cause pain [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    sodium, and others can trigger urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema by two distinct mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Pseudoallergic/pharmacologic",
"       </strong>",
"      </span>",
"      &mdash; NSAIDs cause urticaria in some individuals, presumably due to underlying abnormalities in arachidonic acid metabolism. This form of NSAID reaction is called a pseudoallergic reaction, because the mechanism is nonimmunologic. NSAID pseudoallergy can be seen with any agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ) that inhibits the COX I enzyme, and rarely occurs with agents that are very weak inhibitors of COX I. Patients with pseudoallergy usually tolerate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and the selective COX II inhibitors. Pseudoallergic reactions attributed to NSAIDs are discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link&amp;anchor=H4#H4\">",
"       \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Pseudoallergic reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Allergic",
"      </strong>",
"      &mdash; A specific NSAID can also cause acute urticaria in patients who are allergic to that one agent. These reactions are presumed to represent true, immunologic allergy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link&amp;anchor=H9#H9\">",
"       \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Allergic reactions (presumed IgE-mediated)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both pharmacologic and allergic reactions to NSAIDs can be severe. However, the management differs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link&amp;anchor=H15#H15\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818130\">",
"    <span class=\"h2\">",
"     Uncommon causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncommon causes of new onset urticaria include various physical factors, serum sickness, and hormone-associated disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Physical stimuli",
"      </strong>",
"      &mdash; Physical urticarial syndromes are forms of chronic urticaria that are triggered by specific physical factors, such as cold exposure, sudden changes in body temperature, pressure or vibration against the skin, exercise, exposure to sunlight, or other stimuli. These disorders are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link\">",
"       \"Physical urticarias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=see_link\">",
"       \"Cold urticaria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Serum sickness",
"      </strong>",
"      &mdash; Serum sickness and serum sickness-like reactions to exogenous proteins or medications may present with an urticarial rash, accompanied by fever, polyarthralgias, polyarthritis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymphadenopathy. This typically develops within one to three weeks after administration of the causative agent. Proteinuria, edema, and abdominal pain may also be present. These reactions are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"       \"Serum sickness and serum sickness-like reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Progesterone-associated urticaria",
"      </strong>",
"      &mdash; There are rare reports of progesterone-containing oral contraceptives, hormone replacement therapy, or endogenous progesterone associated with cyclic urticaria [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. The disorder is sometimes called autoimmune progesterone dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/24-27\">",
"       24-27",
"      </a>",
"      ]. Lesions usually appear during the second half of the menstrual cycle and resolve with menstruation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SYSTEMIC DISORDERS THAT MAY INCLUDE URTICARIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncommonly, urticaria or urticarial-like lesions may be an early feature of a systemic disorder, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Urticarial vasculitis",
"      </strong>",
"      : Urticarial vasculitis should be suspected when individual lesions are painful, long-lasting (longer than 24 to 36 hours), appear purpuric or ecchymotic, or leave residual ecchymosis or hyperpigmentation upon resolution (in the absence of trauma from scratching) (",
"      <a class=\"graphic graphic_picture graphicRef54877 \" href=\"UTD.htm?9/45/9939\">",
"       picture 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef66203 \" href=\"UTD.htm?35/25/36240\">",
"       picture 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef77924 \" href=\"UTD.htm?38/53/39760\">",
"       picture 10",
"      </a>",
"      ). Vasculitis should also be suspected in patients with urticaria accompanied by fever, arthralgias, arthritis, weight changes, bone pain, or lymphadenopathy. Urticarial vasculitis may be a cutaneous or systemic disease, or may be part of another rheumatologic disorder, or rarely, a malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"       \"Urticarial vasculitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link\">",
"       \"Cutaneous manifestations of internal malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mastocytosis",
"      </strong>",
"      : Mastocytosis and mast cell disorders are rare conditions in which patients present with apparent allergic reactions and anaphylaxis to a variety of triggers. Characteristic skin findings are helpful in diagnosis. These disorders are reviewed separately (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"       \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Systemic lupus erythematosus, rheumatoid arthritis, Sj&ouml;gren's syndrome, celiac disease, autoimmune thyroid disease, and other autoimmune diseases:",
"      </strong>",
"      Urticaria may be a presenting manifestation or occur sporadically over time in patients with autoimmune conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/28\">",
"       28",
"      </a>",
"      ]. The etiology of this remains unclear but may be due to direct mast cell activation via complement receptors or due to the generation of autoantibodies that may result in anaphylactoid degranulation. Screening for these disorders would not be typical with patients with an acute episode of urticaria, but rather would wait until patients had more chronic symptoms.",
"     </li>",
"     <li>",
"      <strong>",
"       Cutaneous small vessel vasculitis",
"      </strong>",
"      &mdash; Some forms of cutaneous small vessel vasculitis can appear urticarial during early stages. Urticarial lesions that are persistent in a single location for &gt;24 hours, have bruising, are painful, or accompanied by systemic symptoms (eg, fever) should raise a concern for vasculitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Urticarial vasculitis is a disorder characterized by urticarial lesion with vasculitic findings on skin biopsy (",
"      <a class=\"graphic graphic_picture graphicRef66203 \" href=\"UTD.htm?35/25/36240\">",
"       picture 9",
"      </a>",
"      ). The disorder may be systemic or limited to the skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"       \"Urticarial vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis) is a systemic vasculitis with a prominent cutaneous component characterized by purpuric lesions, particularly involving the lower extremities. The skin lesions can be urticarial initially, although the development of systemic disease, with arthralgias, abdominal pain, and renal involvement should prompt investigation for this condition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Skin manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with lupus may also develop urticarial lesions that persist and become vasculitic. Skin biopsy may show evidence of vasculitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Malignancies:",
"      </strong>",
"      Urticaria may also be seen with malignancies, especially IgM and sometimes IgG paraproteinemias. The etiology is also unclear but may be also due to complement mediated pathways.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The urticaria associated with systemic disorders is generally recurrent, persistent, and relatively difficult to treat, so patients with these disorders typically present with chronic urticaria. Clinical features that can help distinguish these disorders from uncomplicated chronic urticaria are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link&amp;anchor=H1264349#H1264349\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818909\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria is diagnosed clinically, based upon a detailed history and physical examination confirming the presence of characteristic skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818923\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history should determine the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Were there other signs and symptoms of a generalized allergic reaction or anaphylaxis? Patients may fail to report more subtle symptoms unless specifically asked. The clinician should ask about chest tightness or difficulty breathing, hoarse voice or throat tightness, nausea, vomiting, crampy abdominal pain, lightheadedness, and other symptoms of anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Has the patient had hives previously in the past? Some children develop acute urticaria repeatedly with infections. Adults may develop urticaria following NSAID ingestion, but not recognize the association until it has occurred several times. Does the patient have other allergic disorders?",
"     </li>",
"     <li>",
"      Were there any symptoms or signs to suggest an underlying systemic disorder? Specifically, have they recently had unexplained fever, weight loss, arthralgias, arthritis, or bone pain [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]? Diseases that may include hives as part of the clinical presentation are reviewed separately. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Systemic disorders that may include urticaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Is a possible etiology apparent from the patient's history (",
"      <a class=\"graphic graphic_table graphicRef54872 \" href=\"UTD.htm?15/35/15932\">",
"       table 1",
"      </a>",
"      )? (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Was the patient in their usual state of health when the hives appeared, or have they been ill recently with viral or bacterial infections? Have they experienced any recent health events, such as musculoskeletal injuries for which they were taking NSAIDs, or new diagnoses requiring unfamiliar medications or treatments?",
"     </li>",
"     <li>",
"      The patient should be asked to review events in the hours before the urticaria appeared. What had they ingested (foods, beverages, candy)? Were they involved in exercise or physical exertion? Were they exposed to extremes of temperature or stung by an insect? The answers may reveal clues to allergic or physical causes of urticaria.",
"     </li>",
"     <li>",
"      Patients should be questioned about any new medications or supplements in the preceding days or weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Were any medications taken in the hours before the urticaria appeared?",
"     </li>",
"     <li>",
"      Inquiries should be made about recent travel (and symptoms of parasitic infection) and sexual history. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A complete review of systems is valuable in the patient with new onset urticaria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7732692\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions should be visualized directly in order to make the diagnosis with certainty, since the term \"hives\" is used nonspecifically by patients. If the patient has no lesions at the time of evaluation, showing patients photographs of urticaria and asking if their lesions look similar can be helpful, although the diagnosis will need to be confirmed at some point in the future (",
"    <a class=\"graphic graphic_picture graphicRef63644 \" href=\"UTD.htm?23/55/24433\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81678 \" href=\"UTD.htm?11/2/11311\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81168 \" href=\"UTD.htm?22/0/22542\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77506 \" href=\"UTD.htm?22/12/22720\">",
"     picture 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62861 \" href=\"UTD.htm?5/37/5712\">",
"     picture 12",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Individual urticarial lesions usually appear and resolve completely within 24 hours. If the patient is unsure of the duration of the lesions, a lesion can be circled with a pen, and time to resolution noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818930\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies are typically normal in patients who lack any history or physical findings to suggest an underlying disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Practice parameters differ somewhat in their recommendations about laboratory studies in a patient with new onset urticaria in whom the clinical history and physical exam do NOT suggest an underlying disorder or urticarial vasculitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      European guidelines recommend that initial laboratory studies be obtained for the purpose of detecting underlying disorders earlier in those one-third of patients in whom the disorder will prove persistent (ie, initial presentation of chronic urticaria), and suggest a complete blood count with differential, urinalysis, erythrocyte sedimentation rate, and liver function tests [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/37\">",
"       37",
"      </a>",
"      ]. However, the diagnostic yield of this approach has not been evaluated.",
"     </li>",
"     <li>",
"      American practice parameters state that a limited evaluation &ldquo;may be considered&rdquo; in such patients and suggest the same tests [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/38\">",
"       38",
"      </a>",
"      ]. The author&rsquo;s approach is to obtain these tests in patients with persistent symptoms.",
"     </li>",
"     <li>",
"      British guidelines state that the diagnosis is primarily clinical and laboratories are not needed in all patients, although if obtained, they should be guided by the clinical history and physical examination [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a specific etiology is suspected, laboratory studies and further evaluation should be directed at establishing or excluding that cause. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Etiologies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818937\">",
"    <span class=\"h3\">",
"     Tests for allergic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;An allergic cause is possible if the clinical history reveals a specific trigger to which the patient was exposed shortly before the onset of symptoms (ie, usually within one to two hours). If the history does suggest a possible allergy, serum tests for allergen-specific IgE antibodies are appropriate, if commercially available. For example, if a patient who does not normally eat seafood, but did so at a special occasion developed hives within 10 minutes of eating a crab cake, it would be reasonable to obtain a crab-specific IgE test, particularly if there were no other new foods ingested and the patient is avoiding seafood for fear of a repeat reaction. However, the interpretation of allergy tests can require some expertise: a positive result is suggestive, although not diagnostic of allergy, and a negative result does not exclude allergy. Because of this, we suggest that patients suspected of having an allergy be referred to an",
"    <span class=\"nowrap\">",
"     allergist/immunologist",
"    </span>",
"    for further evaluation when possible. (See",
"    <a class=\"local\" href=\"#H10819030\">",
"     'Referral'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818951\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conditions discussed in this section are those that may mimic various features of urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/40\">",
"     40",
"    </a>",
"    ]. The presence or absence of pruritus is a helpful clinical feature that can be used to narrow the differential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818958\">",
"    <span class=\"h2\">",
"     Nonpruritic conditions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Viral exanthems",
"      </strong>",
"      &mdash; Viral exanthems are common in children, and can occur with many different infections, including erythema infectiosum (Fifth disease), Epstein-Barr virus, enteroviruses, Kawasaki disease, and measles. However, viral exanthems are generally not pruritic, and usually consist of erythematous maculopapular eruptions that persist for days. Fever is often present. The macules are relatively fixed, as compared to urticarial lesions, which continually change with new lesions appearing as older lesions resolve. (See topic reviews on specific infections).",
"     </li>",
"     <li>",
"      <strong>",
"       Auriculotemporal syndrome",
"      </strong>",
"      &mdash; The auriculotemporal syndrome is a nonpruritic flushing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sweating of the skin over the cheeks or jawline (the areas supplied by the auriculotemporal nerve) that occurs transiently after eating and may be mistaken for urticaria associated with food allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/41\">",
"       41",
"      </a>",
"      ]. It can be seen in children or adults and may develop following damage to the nerve secondary to forceps delivery, viral infection, surgery, or other local trauma. Unilateral distribution is typical, although bilateral cases have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Sweets syndrome",
"      </strong>",
"      &mdash; Sweets syndrome is an uncommon disease characterized by recurrent episodes of painful, long-lasting inflammatory papules and plaques associated with fever, arthralgias, and peripheral leukocytosis. There may be a history of a febrile illness one to three weeks before the onset of skin lesions in some cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40905?source=see_link\">",
"       \"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818966\">",
"    <span class=\"h2\">",
"     Pruritic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritic conditions that are more likely to be confused with urticaria are discussed here. An overview of the causes of pruritic dermatoses is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=see_link\">",
"     \"Pruritus: Etiology and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Atopic dermatitis",
"      </strong>",
"      &mdash; Atopic dermatitis is a common disorder that presents initially as intensely pruritic erythematous patches with papules and some scaling. In children, the face, scalp, extremities, or trunk are typically involved, while the diaper area is spared. In older children and adults, the flexural areas (neck, antecubital fossae, and popliteal fossae) are most commonly involved; other sites include the face, wrists, and forearms (",
"      <a class=\"graphic graphic_picture graphicRef65407 \" href=\"UTD.htm?41/31/42482\">",
"       picture 13",
"      </a>",
"      ). Erythematous areas of involvement last for days or weeks and have ill-defined borders. Scaling and xerosis develop with time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Contact dermatitis",
"      </strong>",
"      &mdash; Contact dermatitis refers to any dermatitis arising from direct skin exposure to a substance. The dermatitis may either be allergic or irritant-induced; the latter is more common. Contact dermatitis is an erythematous, papular dermatitis, often with areas of vesiculation (",
"      <a class=\"graphic graphic_picture graphicRef71913 \" href=\"UTD.htm?33/61/34782\">",
"       picture 14",
"      </a>",
"      ). It is distributed in the areas of direct contact. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=see_link\">",
"       \"Contact dermatitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29001?source=see_link\">",
"       \"Irritant contact dermatitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Drug eruptions",
"      </strong>",
"      &mdash; Drug eruptions, also called morbilliform or exanthematous drug eruptions, are cutaneous drug reactions that closely mimic viral exanthems, but occur in association with a medication. These dermatoses may or may not be pruritic, and begin as small macules",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      papules that become larger and confluent with time (",
"      <a class=\"graphic graphic_picture graphicRef70062 \" href=\"UTD.htm?31/30/32239\">",
"       picture 15",
"      </a>",
"      ). The individual lesions are persistent, unlike urticaria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"       \"Drug eruptions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Insect bites",
"      </strong>",
"      &mdash; Insect bites produce individual lesions that persist for days in most cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=see_link\">",
"       \"Insect bites\"",
"      </a>",
"      .) However, the stings of some insects can cause true urticaria as part of a systemic allergic reaction. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'IgE-mediated allergic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous pemphigoid",
"      </strong>",
"      &nbsp;In older adults, bullous pemphigoid may start with pruritus, with or without urticarial lesions. Blistering usually becomes evident eventually. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290498#H53290498\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Bullous pemphigoid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema multiforme",
"      </strong>",
"      &mdash; Erythema multiforme (EM) minor is a syndrome characterized by erythematous, iris-shaped macules, and vesiculobullous lesions with a target appearance (",
"      <a class=\"graphic graphic_picture graphicRef74095 \" href=\"UTD.htm?40/61/41951\">",
"       picture 16",
"      </a>",
"      ). The lesions may be painful or pruritic and distributed symmetrically on the extensor surfaces of the extremities (particularly the palms and soles). Individual lesions last several days, unlike urticaria. There may be accompanying fever and malaise. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Plant induced reactions",
"      </strong>",
"      &mdash; Poison ivy and poison oak can present with urticarial-like lesions initially that evolve into vesicular lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20168?source=see_link\">",
"       \"Poison ivy (Toxicodendron) dermatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818973\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of new onset urticaria should focus on the short-term relief of pruritus. Approximately two-thirds of cases of new onset urticaria will be self-limited and resolve spontaneously. The literature on management of acute urticaria is sparse, probably because the condition is so often self-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/43\">",
"     43",
"    </a>",
"    ]. The agents discussed below have mostly been evaluated in the treatment of chronic urticaria, and in some cases their use in acute urticaria is extrapolated from those studies, which are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"     \"Chronic urticaria: Standard management and patient education\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818980\">",
"    <span class=\"h2\">",
"     H1 antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;H1 antihistamines may be divided into older, first generation agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    ), and newer, second generation agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    , others).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818988\">",
"    <span class=\"h3\">",
"     Second generation agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newer, second generation H1 antihistamines are recommended as first-line therapy by published guidelines from both Allergy and Dermatology expert panels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/37,44\">",
"     37,44",
"    </a>",
"    ]. These drugs are minimally sedating, essentially free of the anticholinergic effects that can complicate use of first-generation agents, have few significant drug-drug interactions, and require less frequent dosing compared with first generation agents [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/45-49\">",
"     45-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients require higher than standard doses (shown below in parentheses) for control of urticarial symptoms and may experience drowsiness at these higher doses. Caution is therefore warranted until effects upon the individual are understood. The higher doses may have better efficacy in some adults, although this has not been conclusively demonstrated. Studies of higher dose antihistamines for chronic urticaria are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link&amp;anchor=H9#H9\">",
"     \"Chronic urticaria: Standard management and patient education\", section on 'H1 antihistamines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with H1 antihistamines results in clearance of the lesions in some patients, but in others, treatment may only achieve flattening of the lesions and reduction in pruritus, with persistence of erythematous macules. Patients in the latter group can begin to reduce medications after the erythematous lesions clear.",
"   </p>",
"   <p>",
"    Second generation H1 antihistamines are only available in oral formulations and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       Cetirizine",
"      </a>",
"      : Cetirizine demonstrates a rapid onset of action and some mast cell stabilizing activity. It can be mildly sedating, in a dose dependent manner, although less so than first generation agents. The standard dose of 10 mg once daily is appropriate for adults and children ages six years and greater (and may be increased to 10 mg twice daily in adults if needed).",
"      <br/>",
"      <br/>",
"      The usual dose for children aged two to five years is 5 mg once daily. Smaller children aged six months to two years may be given 2.5 mg once daily (can be increased to 2.5 mg twice daily in children one year and older if needed). The maintenance dose for patients with significant renal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatic insufficiency should be reduced by one-half.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44757?source=see_link\">",
"       Levocetirizine",
"      </a>",
"      : Levocetirizine is an active enantiomer of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      and produces effects equivalent to cetirizine at about half the dose. For adults and children 12 years and greater, the standard dose is 5 mg once daily in the evening (or up to 5 mg twice daily in adults if needed) or 2.5 mg once daily in the evening for children aged 6 to 11 years. Levocetirizine is unlikely to be effective as an alternative for patients who acquire tolerance to the effects of cetirizine. Significant dosage alteration is necessary in renal insufficiency (see",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44757?source=see_link\">",
"       \"Levocetirizine: Drug information\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"       Loratadine",
"      </a>",
"      : Loratadine is a long-acting selective H1 antihistamine chemically distinct from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      and has a standard dose of 10 mg once daily for ages six years and greater (or up to 10 mg twice daily in adults if needed). Loratadine is minimally sedating at the standard dose of 10 mg daily.",
"      <br/>",
"      <br/>",
"      For children aged two to five years, the usual dose is 5 mg once daily. For patients with significant renal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatic insufficiency, the usual dose is administered every other day.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"       Desloratadine",
"      </a>",
"      : Desloratadine is the major active metabolite of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      and produces effects equivalent to loratadine at about half the dose. For adults and children 12 years and greater, the standard dose is 5 mg once daily (or up to 5 mg twice daily in adults if needed).",
"      <br/>",
"      <br/>",
"      For children aged 6 to 11 years, the dose is 2.5 mg once daily and for those aged 1 to 5 years the dose is 1.25 mg once daily. A lower dose of 1 mg once daily is approved in the US for small children aged six months to one year. For patients with significant renal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatic insufficiency, the usual dose is administered every other day.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"       Fexofenadine",
"      </a>",
"      : Fexofenadine is minimally sedating. The suggested dose is 180 mg daily for ages 12 years and greater (or up to twice daily if needed in adults) or 30 mg twice daily for children aged 2 to 11 years. A lower dose of 15 mg twice daily is approved in the US for small children aged six months to two years. For patients with significant renal insufficiency, the adult dose should be reduced to 60 mg once daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We know of no data demonstrating that any specific agent is more effective than another for the treatment of acute urticaria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10818995\">",
"    <span class=\"h3\">",
"     First generation agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first generation antihistamines include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    , and others [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/50\">",
"     50",
"    </a>",
"    ]. These agents are lipophilic and readily cross the blood brain barrier, causing sedating and anticholinergic side effects that may be dose-limiting in some patients. Significant sedation and impairment of performance (eg, fine-motor skills, driving skills, and reaction times) occurs in more than 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/51\">",
"     51",
"    </a>",
"    ]. Anticholinergic side effects include dry mouth, diplopia, blurred vision, urinary retention, or vaginal dryness. Patients should be warned specifically about these adverse effects. Despite these adverse effects, patients at low risk of complications (eg, young, healthy patients), may find a sedating H1 antihistamine at bedtime helpful, especially when combined with a nonsedating H1 antihistamine during the day.",
"   </p>",
"   <p>",
"    Some first generation H1 antihistamines are available in parenteral preparations for use in patients in whom a more rapid onset of action is desired, such as those who have presented to the emergency department. Parenteral dosing of the first generation agents is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      : 25 to 50 mg slow intravenous administration or intramuscularly",
"      <span class=\"nowrap\">",
"       (IV/IM)",
"      </span>",
"      in adults, every four to six hours. Children may receive 0.5 to 1.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (up to 50 mg per dose)",
"      <span class=\"nowrap\">",
"       IV/IM",
"      </span>",
"      every six hours as needed.",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       Hydroxyzine",
"      </a>",
"      : 25 to 50 mg deep intramuscular (IM) administration in adults, every four to six hours. Do not administer intravenously. Children may receive 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (up to 50 mg per dose) IM every six hours as needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10819002\">",
"    <span class=\"h3\">",
"     Pregnant and lactating women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women may be treated initially with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    (10 mg once daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    (10 mg once daily). There are reassuring human data for each of these drugs in a large number of pregnant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/52\">",
"     52",
"    </a>",
"    ]. Another option is the first generation agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    , 4 mg orally every four to six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Safety issues surrounding the use of antihistamines in pregnancy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=see_link&amp;anchor=H13#H13\">",
"     \"Recognition and management of allergic disease during pregnancy\", section on 'Antihistamines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lactating women may be treated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    , 10 mg once daily, which is minimally excreted in breast milk and should not cause sedation or poor feeding in the infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link&amp;anchor=H27574600#H27574600\">",
"     \"Pharmacotherapy of allergic rhinitis\", section on 'Breastfeeding women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10819009\">",
"    <span class=\"h2\">",
"     H2 antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of an H1 antihistamine and an H2 antihistamine may be more effective for acute urticaria than an H1 antihistamine alone, although the data are weak [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/55\">",
"     55",
"    </a>",
"    ]. In one randomized trial of 91 adults with acute allergic syndromes (defined as urticaria with or without erythema or angioedema), subjects received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg parenterally) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    (50 mg parenterally), or diphenhydramine plus placebo infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/56\">",
"     56",
"    </a>",
"    ]. At two hours, significantly more patients had resolution of urticarial lesions in the combined treatment group. No differences were noted in the clearance of angioedema or erythema.",
"   </p>",
"   <p>",
"    Options for H2 antihistamines include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/16/29958?source=see_link\">",
"     nizatidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/45/728?source=see_link\">",
"     famotidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , although caution should be used with cimetidine, since it can increase levels of other drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=see_link\">",
"     \"Pharmacology of antiulcer medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10819016\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief course (eg, usually a week or less) of systemic glucocorticoids may be added to antihistamine therapy to control persistent and severe symptoms. Glucocorticoids do not inhibit mast cell degranulation, but probably act by suppressing a variety of contributing inflammatory mechanisms.",
"   </p>",
"   <p>",
"    A small number of trials have examined the utility of glucocorticoids in the management of acute urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In one randomized trial of 42 adults presenting with acute urticaria,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , 50 mg intramuscularly, was given acutely, and patients were discharged on a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    (25 mg orally, every four to eight hours for pruritus) plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 20 mg, or placebo orally twice daily for four days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/24/21898/abstract/57\">",
"     57",
"    </a>",
"    ]. Itching was evaluated at two and five days. In the group receiving prednisone, itching was significantly less, and resolution was more rapid and complete. Thus, the addition of oral glucocorticoids appears to be helpful, although it may not be necessary in many cases.",
"   </p>",
"   <p>",
"    Our approach is to administer oral glucocorticoids, in addition to H1 and H2 antihistamines, to patients whose initial symptoms are severe, and to those with prominent angioedema. A course of glucocorticoids may also be added later for urticaria that is persistent despite antihistamines.",
"   </p>",
"   <p>",
"    The optimal agent and dose have not been determined for acute urticaria, but we typically administer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In adults:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      , 30 to 60 mg daily, with tapering of the dose over five to seven days",
"     </li>",
"     <li>",
"      In children:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      , 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      (maximum 60 mg daily), with tapering of the dose over five to seven days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antihistamine therapy should be continued during and after the course of glucocorticoids, because some patients experience an exacerbation as the glucocorticoids are tapered or discontinued. If symptoms do not recur over several days after stopping glucocorticoids, then antihistamines can be discontinued also. For patients whose symptoms recur when medications are discontinued, antihistamines should be reinstituted and used at the lowest effective dose. Repeated courses of glucocorticoids should be avoided, as the risks of adverse effects outweigh the benefit for most patients. (See",
"    <a class=\"local\" href=\"#H10819030\">",
"     'Referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10819023\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antileukotriene agents have not been studied in the treatment of new onset urticaria. These agents and many others have been evaluated in the treatment of chronic urticaria, as reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link&amp;anchor=H15#H15\">",
"     \"Chronic urticaria: Standard management and patient education\", section on 'Leukotriene modifiers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10819030\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are suspected of having an allergic etiology causing new onset urticaria, such as a food or medication allergy, should be referred to an allergy specialist and may need to be equipped with epinephrine for self-injection. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H39#H39\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Discharge care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It should be explained to patients that about one-third of cases of new urticaria will prove persistent, and that if they continue to have ongoing symptoms after several weeks, they should seek reevaluation in a primary care setting. Patients with difficult to control symptoms may also be referred to a dermatology or allergy specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/47/37617?source=see_link\">",
"       \"Patient information: Hives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=see_link\">",
"       \"Patient information: Hives (urticaria) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urticaria is common, affecting up to 20 percent of the population. Urticarial lesions are intensely pruritic, circumscribed, raised, erythematous plaques, often with central pallor. Morphology and size can vary (",
"      <a class=\"graphic graphic_picture graphicRef78544 \" href=\"UTD.htm?6/47/6896\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef63644 \" href=\"UTD.htm?23/55/24433\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef81678 \" href=\"UTD.htm?11/2/11311\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef81168 \" href=\"UTD.htm?22/0/22542\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urticaria is classified as acute or chronic. Acute urticaria is defined as periodic outbreaks of urticarial lesions that resolve within six weeks, and two-thirds of all urticaria falls into this category. (See",
"      <a class=\"local\" href=\"#H25448761\">",
"       'Categorization of urticaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A presumptive trigger, such as common viral and bacterial infections, medications, food ingestion, or insect sting can sometimes be identified for new onset urticaria. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occasionally, urticaria may be the presenting feature of another systemic disorder, such as urticarial vasculitis, mastocytosis, or systemic lupus erythematous. There are specific clinical features that should prompt an evaluation for these conditions. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Systemic disorders that may include urticaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of urticaria is made clinically. Uncomplicated urticarial lesions are pruritic cutaneous plaques which develop over minutes to hours, and resolve in hours without residual markings (",
"      <a class=\"graphic graphic_picture graphicRef63644 \" href=\"UTD.htm?23/55/24433\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef81678 \" href=\"UTD.htm?11/2/11311\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef81168 \" href=\"UTD.htm?22/0/22542\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef77506 \" href=\"UTD.htm?22/12/22720\">",
"       picture 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef62861 \" href=\"UTD.htm?5/37/5712\">",
"       picture 12",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10818909\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful history should be performed to exclude possible anaphylaxis, identify a possible trigger, and determine if there are signs or symptoms to suggest urticarial vasculitis or an underlying systemic disorder. If the history does not suggest a specific trigger or underlying systemic illness, then laboratory tests are usually normal and not helpful. Some guidelines advocate obtaining a complete blood count with differential, urinalysis, erythrocyte sedimentation rate, and liver function tests at initial presentation, while others suggest testing only if symptoms persist. (See",
"      <a class=\"local\" href=\"#H10818909\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with mild symptoms of new onset urticaria, we suggest treatment with a nonsedating H1 antihistamine alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In patients at low risk of complications from anticholinergic side effects (young, healthy patients), use of a sedating H1 antihistamine at bedtime and a nonsedating H1 antihistamine during the day is a reasonable alternative.",
"     </li>",
"     <li>",
"      In patients with moderate to severe symptoms, in addition to treatment with an H1 antihistamine as above, we suggest treatment with an H2 antihistamine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with severe symptoms, prominent angioedema, or persistent symptoms while taking an H1 and H2 antihistamine, we suggest additional treatment with a brief course of oral glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (20 to 40 mg daily) in adults or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      in children, tapered over five to seven days.",
"     </li>",
"     <li>",
"      Urticaria that persists beyond several weeks may represent the beginning of chronic urticaria, a disorder that is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"       \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kaplan AP. Urticaria and angioedema. In: Middleton's Allergy: Principles and practice, 7th, Adkinson NF, Bochner BS, Busse WW, et al.  (Eds), Mosby, St Louis, MO 2009. Vol 2, p.1063.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/2\">",
"      Sackesen C, Sekerel BE, Orhan F, et al. The etiology of different forms of urticaria in childhood. Pediatr Dermatol 2004; 21:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/3\">",
"      Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002; 346:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/4\">",
"      Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 109:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/5\">",
"      Mortureux P, L&eacute;aut&eacute;-Labr&egrave;ze C, Legrain-Lifermann V, et al. Acute urticaria in infancy and early childhood: a prospective study. Arch Dermatol 1998; 134:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/6\">",
"      Plumb J, Norlin C, Young PC, Utah Pediatric Practice Based Research Network. Exposures and outcomes of children with urticaria seen in a pediatric practice-based research network: a case-control study. Arch Pediatr Adolesc Med 2001; 155:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/7\">",
"      Caubet JC, Kaiser L, Lema&icirc;tre B, et al. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol 2011; 127:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/8\">",
"      Wu CC, Kuo HC, Yu HR, et al. Association of acute urticaria with Mycoplasma pneumoniae infection in hospitalized children. Ann Allergy Asthma Immunol 2009; 103:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/9\">",
"      Shah KN, Honig PJ, Yan AC. \"Urticaria multiforme\": a case series and review of acute annular urticarial hypersensitivity syndromes in children. Pediatrics 2007; 119:e1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/10\">",
"      Cribier B. Urticaria and hepatitis. Clin Rev Allergy Immunol 2006; 30:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/11\">",
"      Friedman D, Picard-Dahan C, Grossin M, et al. Chronic urticaria revealing an HIV infection. Eur J Dermatol 1995; 5:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/12\">",
"      Di Campli C, Gasbarrini A, Nucera E, et al. Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 1998; 43:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/13\">",
"      Del Pozo MD, Aud&iacute;cana M, Diez JM, et al. Anisakis simplex, a relevant etiologic factor in acute urticaria. Allergy 1997; 52:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/14\">",
"      Sussman GL, Beezhold DH. Allergy to latex rubber. Ann Intern Med 1995; 122:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/15\">",
"      Wang J, Sampson HA. Food allergy. J Clin Invest 2011; 121:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/16\">",
"      Bourrain JL. Occupational contact urticaria. Clin Rev Allergy Immunol 2006; 30:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/17\">",
"      Robledo T, Cimarra M, Agustin P, Martinez-Cocera C. Adverse reaction to dextromethorphan. Allergy 2004; 59:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/18\">",
"      Anderson BE, Miller CJ, Adams DR. Stinging nettle dermatitis. Am J Contact Dermat 2003; 14:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/19\">",
"      Cummings AJ, Olsen M. Mechanism of action of stinging nettles. Wilderness Environ Med 2011; 22:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/20\">",
"      Uslu S, Bulbul A, Diler B, et al. Urticaria due to Urtica dioica in a neonate. Eur J Pediatr 2011; 170:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/21\">",
"      Oliver F, Amon EU, Breathnach A, et al. Contact urticaria due to the common stinging nettle (Urtica dioica)--histological, ultrastructural and pharmacological studies. Clin Exp Dermatol 1991; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/22\">",
"      Poole JA, Rosenwasser LJ. Chronic idiopathic urticaria exacerbated with progesterone therapy treated with novel desensitization protocol. J Allergy Clin Immunol 2004; 114:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/23\">",
"      Shank JJ, Olney SC, Lin FL, McNamara MF. Recurrent postpartum anaphylaxis with breast-feeding. Obstet Gynecol 2009; 114:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/24\">",
"      Bandino JP, Thoppil J, Kennedy JS, Hivnor CM. Iatrogenic autoimmune progesterone dermatitis caused by 17alpha-hydroxyprogesterone caproate for preterm labor prevention. Cutis 2011; 88:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/25\">",
"      Le K, Wood G. A case of autoimmune progesterone dermatitis diagnosed by progesterone pessary. Australas J Dermatol 2011; 52:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/26\">",
"      Bernstein IL, Bernstein DI, Lummus ZL, Bernstein JA. A case of progesterone-induced anaphylaxis, cyclic urticaria/angioedema, and autoimmune dermatitis. J Womens Health (Larchmt) 2011; 20:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/27\">",
"      Prieto-Garcia A, Sloane DE, Gargiulo AR, et al. Autoimmune progesterone dermatitis: clinical presentation and management with progesterone desensitization for successful in vitro fertilization. Fertil Steril 2011; 95:1121.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/28\">",
"      Confino-Cohen R, Chodick G, Shalev V, et al. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol 2012; 129:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/29\">",
"      Charlesworth EN. The spectrum of urticaria: All that urticates may not be urticaria. Immunol Allergy Clin North Am 1995; 15:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/30\">",
"      Beltrani VS. Urticaria and angioedema. Dermatol Clin 1996; 14:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/31\">",
"      Charlesworth EN. Urticaria and angioedema: a clinical spectrum. Ann Allergy Asthma Immunol 1996; 76:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/32\">",
"      Beltrani VS. Urticaria: reassessed. Allergy Asthma Proc 2004; 25:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/33\">",
"      Laman SD, Provost TT. Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 1994; 20:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/34\">",
"      Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/35\">",
"      deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997; 278:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/36\">",
"      Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 89:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/37\">",
"      Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/38\">",
"      Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2000; 85:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/39\">",
"      Grattan CE, Humphreys F, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 2007; 157:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/40\">",
"      Weldon D. When your patients are itching to see you: not all hives are urticaria. Allergy Asthma Proc 2005; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/41\">",
"      Sicherer SH, Sampson HA. Auriculotemporal syndrome: a masquerader of food allergy. J Allergy Clin Immunol 1996; 97:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/42\">",
"      Karunananthan CG, Kim HL, Kim JH. An unusual case of bilateral auriculotemporal syndrome presenting to an allergist. Ann Allergy Asthma Immunol 2002; 89:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/43\">",
"      Beno SM, Nadel FM, Alessandrini EA. A survey of emergency department management of acute urticaria in children. Pediatr Emerg Care 2007; 23:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/44\">",
"      Grattan C, Powell S, Humphreys F, British Association of Dermatologists. Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 2001; 144:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/45\">",
"      Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001; 107:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/46\">",
"      Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/47\">",
"      Purohit A, Melac M, Pauli G, Frossard N. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol 2004; 92:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/48\">",
"      Simons FE, Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatr Allergy Immunol 2007; 18:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/49\">",
"      Garg G, Thami GP. Comparative efficacy of cetirizine and levocetirizine in chronic idiopathic urticaria. J Dermatolog Treat 2007; 18:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/50\">",
"      Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/51\">",
"      Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med 1997; 157:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/52\">",
"      K&auml;ll&eacute;n B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002; 11:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/53\">",
"      Schatz M, Petitti D. Antihistamines and pregnancy. Ann Allergy Asthma Immunol 1997; 78:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/54\">",
"      Schatz M, Zeiger RS. Asthma and allergy in pregnancy. Clin Perinatol 1997; 24:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/55\">",
"      Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev 2012; 3:CD008596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/56\">",
"      Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/57\">",
"      Pollack CV Jr, Romano TJ. Outpatient management of acute urticaria: the role of prednisone. Ann Emerg Med 1995; 26:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/24/21898/abstract/58\">",
"      Zuberbier T, Iffl&auml;nder J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol 1996; 76:295.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8101 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-DA0D917308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21898=[""].join("\n");
var outline_f21_24_21898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25448761\">",
"      CATEGORIZATION OF URTICARIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25448768\">",
"      Acute urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25448775\">",
"      Chronic urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10818075\">",
"      Common causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - IgE-mediated allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Direct mast cell activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10818130\">",
"      Uncommon causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SYSTEMIC DISORDERS THAT MAY INCLUDE URTICARIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10818909\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10818923\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7732692\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10818930\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10818937\">",
"      - Tests for allergic causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10818951\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10818958\">",
"      Nonpruritic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10818966\">",
"      Pruritic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10818973\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10818980\">",
"      H1 antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10818988\">",
"      - Second generation agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10818995\">",
"      - First generation agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10819002\">",
"      - Pregnant and lactating women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10819009\">",
"      H2 antihistamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10819016\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10819023\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10819030\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8101\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8101|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/47/6896\" title=\"picture 1\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/2/29728\" title=\"picture 2\">",
"      Urticaria 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/55/24433\" title=\"picture 3\">",
"      Urticaria 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/2/11311\" title=\"picture 4\">",
"      Giant urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/0/22542\" title=\"picture 5\">",
"      Acute urticaria child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/58/42912\" title=\"picture 6\">",
"      Cholinergic urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/16/27905\" title=\"picture 7\">",
"      Urticarial drug eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/45/9939\" title=\"picture 8\">",
"      UV lesions III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/25/36240\" title=\"picture 9\">",
"      UV lesions I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/53/39760\" title=\"picture 10\">",
"      UV lesions II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/12/22720\" title=\"picture 11\">",
"      Urticaria 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/37/5712\" title=\"picture 12\">",
"      Coalescing urticarial les",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/31/42482\" title=\"picture 13\">",
"      Severe atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/61/34782\" title=\"picture 14\">",
"      Allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/30/32239\" title=\"picture 15\">",
"      Morbilliform eruption 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/61/41951\" title=\"picture 16\">",
"      Erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8101|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15932\" title=\"table 1\">",
"      Causes of urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21068\" title=\"table 2\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/20/36172\" title=\"table 3\">",
"      Symptoms and signs of anaphylaxis in infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37465?source=related_link\">",
"      ACE inhibitor-induced angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=related_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39286?source=related_link\">",
"      Bedbugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=related_link\">",
"      Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=related_link\">",
"      Chronic urticaria: Standard management and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=related_link\">",
"      Cold urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=related_link\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29001?source=related_link\">",
"      Irritant contact dermatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44757?source=related_link\">",
"      Levocetirizine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=related_link\">",
"      Mast cells: Development, identification, and physiologic roles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/47/37617?source=related_link\">",
"      Patient information: Hives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=related_link\">",
"      Patient information: Hives (urticaria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=related_link\">",
"      Pharmacology of antiulcer medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=related_link\">",
"      Physical urticarias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20168?source=related_link\">",
"      Poison ivy (Toxicodendron) dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=related_link\">",
"      Pruritus: Etiology and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36615?source=related_link\">",
"      Reactions to bites from kissing bugs (Triatoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=related_link\">",
"      Recognition and management of allergic disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/61/16346?source=related_link\">",
"      Seafood allergies: Fish and shellfish",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40905?source=related_link\">",
"      Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=related_link\">",
"      Urticarial vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=related_link\">",
"      Vancomycin hypersensitivity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_24_21899="Preventing dietary lead exposure";
var content_f21_24_21899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nutritional interventions to prevent lead exposure and absorption",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Provide a balanced diet that provides a combination of fruits, vegetables, grains, protein, and dairy products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ensure children receive sufficient amounts of calcium, iron, zinc, and vitamin C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce consumption of foods high in fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not store food or liquids in lead crystal glassware or imported or old pottery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you reuse plastic bags to store or carry food, keep the printing on the outside of the bag",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid eating produce that is grown in soil with a high lead content or sprayed with insecticides that contain lead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        If lead-contaminated water is a concern:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Flush pipes for one minute before drinking water or using it for cooking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Use only cold water for cooking, drinking, or preparing infant formula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Consider buying a HEPA* filter certified for lead removal. Call the Environmental Protection Agency's Safe Drinking Water Hotline: 800-426-4791.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * High-efficiency particulate air.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: www.epa.gov/lead/educationexesum.htm and www.psr.org/childled.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21899=[""].join("\n");
var outline_f21_24_21899=null;
var title_f21_24_21900="Pain control for venipuncture and IV placement in children";
var content_f21_24_21900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Behavioral methods and pharmacologic options for venipuncture and IV placement in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Start time before procedure (minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Behavioral methods*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preparation",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Relaxation",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breathing",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distraction",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Encourage coping",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Positioning",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Positive reinforcement",
"       </td>",
"       <td>",
"        After procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Selected pharmacologic options",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lidocaine/prilocaine cream (eg, EMLA&reg;)",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liposomal lidocaine (eg, LMX&reg;) or Tetracaine gel (eg, Ametop&reg;&bull;)",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lidocaine iontophoresis",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Needle-free lidocaine delivery",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lidocaine infiltration",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vapocoolant spray",
"       </td>",
"       <td>",
"        15 seconds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nitrous oxide",
"       </td>",
"       <td>",
"        &nbsp;&lt; 1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All behavioral methods should be continued throughout the procedure, preferably by a dedicated child life specialist.",
"     <br>",
"      &bull; Tetracaine gel is an ester type local anesthetic and is not commercially available in the US. It is widely available elsewhere.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zempsky, WT. Optimizing the management of peripheral venous access pain in children: Evidence, impact, and implementation. Pediatrics 2008; 122 Suppl 3:S121.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21900=[""].join("\n");
var outline_f21_24_21900=null;
var title_f21_24_21901="Rx strep PVE I";
var content_f21_24_21901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of prosthetic valve endocarditis due to penicillin-susceptible viridans streptococci and Streptococcus bovis (minimum inhibitory concentration &le;0.12 &micro;g/mL)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        American Heart Association",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        European Society of Cardiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adult (for patients with normal renal function)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pediatric (not to exceed dose of normal adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 24 million units per 24 h IV either continuously or in 4 or 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone* 2 g per 24 h IV or IM in 1 dose for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          with or without",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 h IV or IM in 1 dose or 3 equally divided doses for 2 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h unless concentrations in serum are inappropriately low for 6 wks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 300,000 units per kg per 24 h IV in 4 or 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone* 100 mg/kg per 24 h IV or IM in 1 dose for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          with or without",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &bull;",
"         </sup>",
"         3 mg/kg per 24 h IV or IM in 1 dose or in 3 equally divided doses for 2 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         40 mg/kg per 24 h IV in 2 or 3 equally divided doses for 6 wks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 12 to 18 million units per 24 h IV in 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Amoxicillin 100 to 200 mg/kg per 24 h IV in 4 to 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 12 g per 24 h (or 100-200 mg/kg per 24 h) IV in 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone* 2 g per 24 h IV or IM in 1 dose for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         30 mg/kg per 24 h IV in 2 equally divided doses for 6 wks",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenously; IM: intramuscularly; h: hours; wks: weeks.",
"     <br/>",
"     * Alternative in patients with non-immediate penicillin allergy; preferred for outpatient therapy; IM administration is painful.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Gentamicin can be eliminated in patients with potential for nephrotoxicity and should not be administered in patients with creatinine clearance &lt;30 mL/min. In adults aminoglycosides are dosed based on ideal body weight.",
"     <br/>",
"     &Delta; Vancomycin therapy only recommended for patients allergic to penicillins or cephalosporins. In adults vancomycin is dosed based on actual body weight. The dose should be adjusted for peak serum concentrations (1 h after infusion) of 30-45 &micro;g/mL and trough concentration of 15-20 &micro;g/mL. The dose may need to be increased beyond 30 mg/kg actual body weight and frequency may need to be increased to 3 equally divided doses.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American Heart Association--executive summary: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:3167.",
"      </li>",
"      <li>",
"       Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30:2369.",
"      </li>",
"      <li>",
"       Liu Catherine, et al. Clinical Practice guidelines by the Infectious Disease Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. CID 2011; 52:285-292.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21901=[""].join("\n");
var outline_f21_24_21901=null;
var title_f21_24_21902="Irinotecan plus cisplatin for advanced gastric cancer";
var content_f21_24_21902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy regimens for advanced esophagogastric cancer: Irinotecan plus cisplatin",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 42 days (six weeks).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        30 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline and administer over 30 minutes. Do not administer with aluminum needles or intravenous sets.",
"       </td>",
"       <td>",
"        Days 1, 8, 15, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Irinotecan",
"        </strong>",
"       </td>",
"       <td>",
"        65 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 mL 5 percent dextrose in water and administer over 30 minutes immediately following cisplatin.",
"       </td>",
"       <td>",
"        Days 1, 8, 15, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard prophylactic premedication regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Routine primary prophylaxis with G-CSF is not indicated (incidence of febrile neutropenia was 7 percent in one study",
"        <sup>",
"         [1]",
"        </sup>",
"        ). However in another study, 6 of 35 patients (17 percent) required hospitalization for toxicity, most commonly for neutropenic fever",
"        <sup>",
"         [3]",
"        </sup>",
"        . The decision to use G-CSF should be individualized, depending on other risk factors for prolonged neutropenia. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. The original clinical trials required a baseline serum creatinine &le;1.5 mg/dL",
"        <sup>",
"         [1,3]",
"        </sup>",
"        . A lower starting dose of irinotecan may be needed for patients with hepatic or severe renal impairment",
"        <sup>",
"         [4]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramping and/or diarrhea within 24 hours of receiving irinotecan, give atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel (creatinine and electrolytes) and liver function tests prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for neurotoxicity prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        On each day of treatment, the white blood cell count should be &ge;3000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        with absolute neutrophil count &ge;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelets &ge;100,000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        <sup>",
"         [3]",
"        </sup>",
"        . Treatment delays up to one week are permitted without dose reduction. Decrease irinotecan dose by 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for hematologic toxicity resulting in treatment delay of more than two weeks, febrile neutropenia, or bleeding complications from thrombocytopenia. If hematologic toxicity causes delay of day 22 therapy, shorten treatment course to three weeks (eliminate day 22) with a two week rest period in between cycles",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Mucositis or diarrhea:",
"        </strong>",
"        Delay treatment for one week if grade &gt;2 diarrhea or mucositis on the day of treatment and further delayed if toxic effects do not diminish to grade &le;1",
"        <sup>",
"         [1,3]",
"        </sup>",
"        . Reduce subsequent irinotecan doses by 10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for grade 3 or 4 diarrhea or mucositis. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Renal toxicity:",
"        </strong>",
"        In the original protocol, the cisplatin dose was reduced to 15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        if serum creatinine increased to &gt;1.7 mg/dL but remained less than 2.0 mg/dL",
"        <sup>",
"         [3]",
"        </sup>",
"        . FDA labeling for cisplatin recommends that subsequent doses of cisplatin be withheld until the serum creatinine is less than 1.5 mg/dL and/or blood urea nitrogen is less than 25 mg/dL",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; G-CSF: granulocyte colony-stimulating factor; CBC: complete blood count.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Ajani JA, et al. Cancer 2002; 94:641.",
"      </li>",
"      <li>",
"       Cisplatin injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).",
"      </li>",
"      <li>",
"       Ilson DH, et al. J Clin Oncol 1999; 17:3270.",
"      </li>",
"      <li>",
"       Camptosar (Irinotecan hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21902=[""].join("\n");
var outline_f21_24_21902=null;
var title_f21_24_21903="Side leg raise video";
var content_f21_24_21903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PC/50656/Side_leg_raise_video.mp4?title=Side+leg+raise+video\" style=\"width:480px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strength exercise video: Side leg raise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise strengthens hips, thighs, and buttocks. For an added challenge, you can modify the exercise to improve your balance.",
"    <br>",
"     <ol>",
"      <li>",
"       Stand behind a sturdy chair with feet slightly apart, holding on for balance. Breathe in slowly.",
"      </li>",
"      <li>",
"       Breathe out and slowly lift one leg out to the side. Keep your back straight and your toes facing forward. The leg you are standing on should be slightly bent.",
"      </li>",
"      <li>",
"       Hold position for one second.",
"      </li>",
"      <li>",
"       Breathe in as you slowly lower your leg.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 times.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 times with other leg.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 more times with each leg.",
"      </li>",
"     </ol>",
"     As you progress, you may want to add ankle weights.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_24_21903=[""].join("\n");
var outline_f21_24_21903=null;
